The Saline Oscillation Hypothesis: Endocannabinoid-Mediated Fungal-Hominid Coevolution in the East African Rift Valley
Jim Craddock
Redacted Science Research Initiative
redactedscience.org | jimcraddock.com
August 2026 V9
https://doi.org/10.5281/zenodo.19369715
PART II
------------------------------------------------------------------
VI. Clinical Application: Cannabinoid Hyperemesis Syndrome as a Potential Host-Organism Interface Disruption
VI.I The Syndrome and Its Gaps
Cannabinoid hyperemesis syndrome (CHS) was first described by Allen et al. (2004) in a case series of 19 patients in South Australia who presented with cyclical vomiting illness linked to chronic, heavy cannabis use. An index case was retrospectively identified to 1996 (Sorensen et al., 2017). The clinical triad consists of severe cyclical vomiting, abdominal pain, and compulsive hot bathing or showering, with the only consistently effective treatment being complete cessation of cannabis use. The syndrome follows a characteristic three-phase pattern: a prodromal phase of morning nausea lasting months to years, a hyperemetic phase of violent vomiting with dehydration, and a recovery phase following cannabis cessation (Simonetto et al., 2012). This doesn't sound fun, does it?
Reported incidence has risen sharply alongside legalization and increased potency. Modern vape concentrates deliver 70-90% THC compared to 15-25% in traditional flower, and recent data indicate that exclusive vape users develop CHS symptoms significantly faster than flower users. Emergency department visits attributable to CHS have increased across all legalized jurisdictions.
The standard pharmacological model describes CHS as a "paradoxical reaction" to chronic THC exposure, and it rests on three observations that lack consensus mechanistic explanations:
Gap 1: Differential CB1 receptor downregulation. In the brain, chronic THC exposure causes well-characterized CB1 receptor downregulation and internalization, weakening the drug's anti-emetic effect (Sim-Selley, 2003). In the gastrointestinal tract, CB1 receptors do not appear to undergo equivalent downregulation. That's weird, right? Gut motility suppression (gastric stasis) persists or intensifies under chronic exposure (Sharkey and Wiley, 2016). This tissue-specific asymmetry is documented but treated as a brute fact in the existing literature, with no proposed mechanism for why gut receptors should behave differently from brain receptors under the same ligand load.
Gap 2: TRPV1 receptor dysregulation. Chronic cannabinoid exposure is thought to inactivate TRPV1 receptors in the gut, contributing to nausea and visceral pain (Izzo et al., 2003). The mechanism by which chronic CB1 agonism produces TRPV1 inactivation across a different receptor class remains unclear. The standard literature waves its hands at this one.
Gap 3: The hot shower phenomenon. CHS patients exhibit a compulsive drive toward hot showers or baths, which provide temporary but often dramatic symptom relief. The standard explanation invokes TRPV1 reactivation by heat, but this raises a circular dependency: if TRPV1 is inactivated by chronic cannabinoid exposure, why would a brief thermal stimulus produce immediate relief that pharmacological CB1 manipulation cannot?
No existing model unifies these three observations under a single mechanism. No prior work in the published literature has proposed C. albicans as a mechanistic contributor to CHS. So, they have no explanation. Enter Redacted Science.
However, the standard model's difficulties extend beyond these three gaps. A 2025 transcriptomic study of CHS patients, Meltzer et al. (2025), looked for the ECS transcript changes the standard model predicts and found none. No significant changes in endocannabinoid system-related transcripts were detected. Instead, the study found marked adaptive immune activation: B-cell immunoglobulin upregulation, altered T-cell, monocyte, and neutrophil expression, impaired gut barrier function with increased matrix degradation and reduced adhesion, MHC Class I upregulation, and IgE receptor downregulation consistent with elevated IgE levels. The authors interpreted these findings as evidence of an "acquired, gut-restricted, immune-mediated hypersensitivity response to cannabis." [Hmm.]
The immune profile they found is notable for what it resembles. C. albicans colonization triggers mast cell degranulation, IgE elevation, Th2 immune skewing, and gut barrier degradation through candidalysin and hyphal invasion, as described in §4 and §5 of this paper. The transcriptomic study found the organism's downstream immune signature and attributed it to cannabis hypersensitivity because the organism was not in their model. The absence of ECS transcript changes is equally significant. The standard model predicts that if CB1 receptors are being disrupted, that disruption should show up in gene expression data. It did not. But the organism does not maintain receptors by changing what genes the host expresses. It maintains them at the protein level, through direct signaling at the cell surface. That is a different layer entirely, one that a transcriptomic study would not detect. The researchers looked at the gene expression layer. The organism works at the protein layer. They found nothing where they looked because the action is happening where they did not look.
VI.II The Biochemical Computer Framework Applied to CHS
The framework presented in this paper offers a potential explanation that resolves all three gaps simultaneously. This section presents the mechanistic logic as a hypothesis to be tested by the experimental predictions in §VI.VI Whether or not every detail proves accurate, the framework generates specific, falsifiable predictions that the standard model does not. That said, calling this a "hypothesis" is a hedge. I am working with a model that no one else has built. My call.
VI.II.I Organism Maintenance of Gut CB1 Receptor Density
As described in §4, C. albicans uses the endocannabinoid system as a primary signaling interface with the host. The organism resides primarily in the gastrointestinal tract. Gut CB1 receptors are therefore the organism's principal broadcast interface with local host tissue.
The organism lives in the gut and talks to the host through CB1 receptors. It needs those receptors to stay active. If it is actively maintaining them (and it can), keeping the locks on the doors it uses, then the differential downregulation in CHS is not paradoxical at all. Gut CB1 receptors resist desensitization because the organism is protecting its own communication channel. Brain CB1 receptors, far from the organism's home territory, have no such protection. They downregulate normally.
This would resolve Gap 1. The gut is not mysteriously resistant to CB1 desensitization. Something in the gut environment is actively maintaining receptor density. The candidate is the resident organism.
VI.II.II Arachidonic Acid Substrate Competition
The host's ECS and C. albicans are drawing from the same raw material supply. Both need arachidonic acid (AA), a fatty acid stored in cell membranes. The host uses it to build its own cannabinoid signaling molecules, anandamide and 2-AG, which keep the gut moving properly and suppress nausea. The organism uses the same AA to manufacture prostaglandin E₂, an inflammatory signal it deploys for immune modulation (Erb-Downward and Noverr, 2007). There is one pool. Two competing users.
The competition runs deeper than two separate production lines pulling from one supply. The host enzyme COX-2 can directly convert endocannabinoid precursors into prostaglandin-family molecules, and when the body breaks down its own cannabinoids, the leftover arachidonic acid becomes available for the organism to capture. The plumbing between these two systems is shared at multiple points. When fungal burden is high, the organism pulls more AA toward its own PGE₂ production, and the host's cannabinoid supply drops. The body's internal anti-nausea system loses its raw materials.
Now layer chronic high-dose THC on top of this depleted substrate pool. The exogenous agonist floods remaining receptors. Brain receptors downregulate normally. Gut receptors are held open by the organism. Endogenous tone is already depleted by substrate competition. The system has three variables collapsing simultaneously: depleted endocannabinoid floor, brain receptor downregulation, and maintained gut receptor density. This is not a two-variable paradox. It is a three-variable system crash.
VI.II.III The Glucose Feedback Loop and the Morning Nausea Pattern
During hyperemetic episodes, patients cannot eat. Blood glucose drops. The Hgt4 glucose sensor in C. albicans, calibrated to human blood glucose concentrations of approximately 5 mM (Brown et al., 2006; see §4.1), detects this decline. Below the 5 mM threshold, the organism shifts operational mode, consistent with the glucose override subroutine described in §5, Prediction 12. To be direct about what this means: when blood glucose falls below the level the organism is calibrated to monitor, it begins sourcing substrate from the host. The host becomes the snack.
This creates a positive feedback loop: vomiting prevents eating, glucose drops below the organism's calibrated threshold, the organism sustains or intensifies its crisis-mode operation, and vomiting continues. The emetic episode creates the metabolic conditions that perpetuate it.
The glucose mechanism receives independent support from the temporal pattern of CHS symptoms. Morning nausea is a defining feature of the prodromal phase (Simonetto et al., 2012). This is the period of lowest blood glucose in the 24-hour cycle. After an overnight fast, circulating glucose approaches its daily nadir. If the organism's Hgt4 sensor is calibrated to approximately 5 mM, the overnight fasting period represents the interval during which blood glucose is most likely to fall near or below this threshold. The morning timing of prodromal nausea is not random. It maps directly onto the predicted glucose-dependent activation window.
The longitudinal case study provides a corroborating observation. During a period of approximately two to four weeks, the case subject (not a CHS patient, but an individual with documented long-term C. albicans colonization) experienced pronounced morning nausea upon waking, a symptom not typical of the broader condition at that stage. Having independentlyrecognized that caloric intake served as a systemic override in this condition, the subject responded by eating immediately and aggressively upon waking: simple carbohydrates first (for rapid glucose elevation above the 5 mM threshold), followed by proteins and fats (for sustained glucose maintenance). The nausea resolved each time. The eating window was approximately thirty minutes of sustained caloric loading.
This response is the inverse of the CHS patient's typical trajectory. CHS patients wake nauseated, the nausea escalates, vomiting prevents eating, glucose remains below the threshold, and the positive feedback loop locks shut. The longitudinal case subject was able to eat through the nausea because, in that clinical context, the emetic reflex was suppressed by the organism rather than destabilized (see §6.4). The same morning glucose trigger produced opposite outcomes depending on whether the organism maintained or lost control of the emetic gate.
Interlude from the Architect
A break from the formal interpretation.
What I have is not CHS. However, I have been through more than I can ever fully communicate in a scientific paper. That does not mean I would change my decision to save my life by accepting this condition, but it does give me a wealth of experiential knowledge that no one else has. In the original redacted article, the author made it clear that the subjects who ate through everything, across all phases except one specific period in the final stage, were the longest-lived. One photograph described in Redacted Science (p. 43, "The Mouth Still Works") shows two figures in the terminal stage. I paraphrased the caption: "At this stage, they are expected to die within a day or two. But they still chew. Because they remember what they've been trained to do. Eat. No matter what."
So when the morning nausea hit, I had that knowledge in my head. I got up, went into the kitchen, and started eating. I was not discriminating. I did not focus specifically on protein, or carbs, or fats. I ate whatever was handy, and I mixed it up on purpose. My advice is simple: eat through the morning nausea, fuel up the tank, and maybe you will have a better day.
How did I eat through nausea? Training. There is an earlier stage of progression when even looking at food triggers a full-body gag reflex, but the vomiting reflex has already been disabled, so nothing comes up. Try shoving food down your throat when every bite triggers gagging with no corresponding stomach emptying. I have very specific memories of eating at a restaurant, gagging on every bite, with my family encouraging me to keep going. So, yes, I had training. But that morning nausea is different. It does not come with gagging. It feels like what it is: blood sugar related nausea.

VI.II.IV TRPV1, the Hot Shower Phenomenon, and the Palliative Trap
[VI.II.IV is pretty cool] To understand why hot showers work in CHS, it helps to understand what TRPV1 actually is. TRPV1 (transient receptor potential vanilloid type 1) is a receptor expressed throughout the gut and the skin. It responds to three categories of stimulus: noxious heat above 43°C (109°F), the temperature of a hot shower; chemical signals like capsaicin, the compound that makes chili peppers burn; and endogenous lipid molecules including anandamide and N-arachidonoyl dopamine, the feel-good molecules your body makes on its own. When activated, TRPV1 produces vasodilation (blood vessel widening) and, under sustained stimulation, defunctionalization, a temporary state in which the receptor stops responding to further input. Both of these effects are directly relevant to pain relief and gut motility.
TRPV1 falls within the receptor range through which the organism interacts with host physiology (CB1, CB2, TRPV1, GPR55). If the organism is managing TRPV1 as part of how it runs the gut, then flooding the system with THC does not just jam the cannabinoid channel. It disrupts the organism's coordinated management of everything it touches, and TRPV1 gets caught in the cascade. The TRPV1 problem in CHS is not a direct effect of cannabis on heat receptors. It is collateral damage from the organism losing its grip on the whole signaling panel.
This is why hot water works. It does not fix the underlying disruption. It bypasses it. Heat hits TRPV1 directly, a raw physical signal that does not pass through the organism's signaling layer at all. For a few minutes, the receptor responds to something other than the organism's management. The vasodilation alone would reduce visceral pain. The defunctionalization temporarily quiets the pain signaling cascade entirely. Capsaicin cream, a direct TRPV1 agonist used successfully in some CHS cases (Dezieck et al., 2017), works the same way. Both engage TRPV1 on its own terms, outside the organism's control. Both provide immediate relief.
What happens when the stimulus ends is the more interesting question. Does the organism's management reassert immediately? Or does the TRPV1 defunctionalization persist for some window afterward, providing a period of genuine receptor silence that outlasts the shower itself? The compulsive return pattern, showering fifteen times a day, suggests the relief window has a consistent duration, and patients learn exactly when it expires.
This resolves Gaps 2 and 3 simultaneously. No hand waving required. TRPV1 dysregulation is downstream of organism signaling disruption, not a direct cannabinoid effect. Hot shower relief is a physical override of an organism-mediated receptor state, which explains both its immediacy and its finite duration.
However, the clinical behavior surrounding hot showers in CHS reveals something beyond simple symptom relief. Case reports describe patients showering up to fifteen times per day, sometimes for over an hour per session (Mohammed et al., 2013). The behavior is consistently described in the clinical literature as "compulsive." This is not the pattern of a patient managing pain with a known palliative intervention. It is the pattern of a patient returning repeatedly to the only state in which they feel substantially better, or perhaps substantially normal, a distinction the clinical literature has not explored.
If the TRPV1 override temporarily restores autonomic function to an unmanaged state, the subjective experience would not be neutral relief. It would be the sensation of a system briefly running without organism interference. For a patient whose gut motility, thermoregulation, and visceral sensation have been continuously managed by the organism, this would register not merely as the absence of nausea but as something closer to wellbeing. The compulsive quality of the behavior is itself evidence that the shower produces a positive experience disproportionate to simple symptom palliation. If the patient has also eaten, the experience exceeds normal and approaches something a healthy person would simply call "feeling good."
There is an additional clinical feature that connects the shower behavior to the glucose mechanism. CHS patients frequently report feeling cold, sometimes profoundly so, during prodromal and hyperemetic episodes. This is typically attributed to autonomic dysfunction or thermoregulatory disruption from chronic cannabinoid exposure. But feeling cold is also a well-documented symptom of low blood sugar. When blood glucose drops, the body constricts peripheral blood vessels to preserve core circulation, and the subjective result is a chill that no amount of blankets resolves. If the morning nausea is glucose-driven (§6.2.3), the cold sensation that accompanies it is the same glucose signal presenting through a different channel. The patient
feels cold and nauseated simultaneously, and the hot shower addresses the cold directly while the TRPV1 override addresses the nausea. The shower solves both symptoms at once. Of course they get in the shower. It is the one intervention that addresses both presentations of the same underlying problem. But neither symptom is caused by the shower's absence. Both are caused by an empty tank.
This creates a palliative trap with direct relevance to the glucose mechanism. Every hour a CHS patient spends in the shower is an hour they are not eating. The shower provides sufficient relief to prevent the patient from pursuing the intervention that would actually break the cycle: caloric loading to raise blood glucose above the organism's Hgt4 threshold. The shower is good enough to sustain the patient in the acute state without resolving it. The real exit is caloric, not thermal. But the thermal relief is compelling enough to keep the patient from finding it, and once vomiting has begun in earnest, the opportunity to eat has passed. Get up and eat. Donuts, sausage, nuts, whatever is within reach. Eat first, shower second.
The standard clinical advice for CHS is hydration and cannabis cessation. No current guideline recommends aggressive caloric loading during the prodromal or early hyperemetic phase. In the glucose override model, this is the critical missing intervention.
VI.III The CBD Paradox
Recent work by Bahraminia et al. (2024) demonstrated that cannabidiol (CBD), at concentrations of 10-20 μg/mL, significantly decreases the growth of C. albicans, inhibits the yeast-to-hyphae transition (from 20% to 2% at 20 μg/mL), reduces biofilm formation, and induces C. albicans death through an apoptosis/necrotic pathway. CBD is not merely modulating receptor access. It is directly antifungal against the organism itself.
This creates a paradox with clinical implications for CHS. If CHS is organism-mediated, then CBD should theoretically address the root cause by reducing fungal burden. However, the acute response to CBD in a colonized host may be more immediate and more dramatic than gradual die-off would predict. This is not something we can model precisely. CHS patients carry elevated but not extreme C. albicans colonization density and are not Homo candidus. Their response may be significantly milder than what follows.
The longitudinal case study provides a relevant observation. On two separate occasions, the case subject (not a CHS patient, but an individual with documented long-term C. albicans colonization) experienced acute respiratory constriction within hours of small-dose CBD exposure (Craddock, Redacted Science). The response was immediate, dramatic, and short-lived, resolving within two to three hours both times. The second exposure was deliberate, to confirm the response was real and reproducible. It was.
The speed and brevity of this response is notable given CBD's pharmacokinetics. CBD has a half-life of 18-32 hours for a single dose, is fat-soluble, and can remain in the body for days in typical individuals. The acute respiratory response resolved in 2-3 hours while the drug should have been circulating at near-peak concentration. This rules out drug clearance as the mechanism of resolution in the standard pharmacokinetic model. However, a caveat applies to the longitudinal case specifically: the case subject's condition has substantially altered fat tissue permeability and distribution due to cellular changes (Craddock, Redacted Science). Fat-soluble storage, the primary mechanism for CBD's long half-life, may not function normally. The 2-3 hour resolution in this case may therefore reflect altered clearance in addition to, or instead of, organism compensation. In a typical CHS patient with normal fat tissue, CBD would remain active for considerably longer.
CBD is a negative allosteric modulator at CB1 and CB2, meaning it changes the shape of the receptors so that other molecules, including whatever the organism is producing, cannot engage them as effectively. The effect is less like killing the organism and more like changing the locks on every door it uses. The organism is still alive, still present, but suddenly unable to communicate through the interface it depends on. In a system where the organism has been actively maintaining respiratory and autonomic tone through ECS-mediated signaling, the abrupt loss of that signaling channel produces acute physiological disruption.
The resolution while CBD should have remained active suggests one of two mechanisms, or a combination of both. First, the organism may have compensated in real time, rerouting its signaling through alternative pathways outside CBD's allosteric range. The framework describes a multi-receptor interface (CB1, CB2, TRPV1, GPR55, cholinergic, prostaglandin), and CB1/CB2 are the primary but not the only channels available. Second, the case subject's compromised fat tissue may have accelerated CBD clearance beyond the standard pharmacokinetic model. Within 2-3 hours, normal function returned. The exhaustion that followed (an uncharacteristic nap) is consistent with either explanation: the metabolic cost of an emergency signaling reroute, or the physiological aftermath of an acute drug effect that cleared faster than expected. By evening, function was normal, running on backup wiring with the primary channel still blocked, or possibly cleared faster than expected given the absence of normal fat-soluble storage and differentiated circulation features. The standard half-life figures assume normal adipose tissue and circulation. This case does not have either.
The case subject described the acute experience in direct terms: "I am alert. I cannot breathe. I have zero energy. One more CBD dose, and I may die." This subjective intensity should be understood in context: the longitudinal case involves an extreme colonization density in which the organism is actively managing respiratory and autonomic function, a degree of organism integration far beyond what is expected in the typical CHS patient population. In a patient with elevated but not extreme gut colonization, the acute CBD response may be mild or imperceptible.
CBD therefore acts on the organism through two distinct mechanisms operating on different timescales. Acutely, it changes the locks: receptor conformation shifts that cut the organism off from its signaling interface within hours, producing immediate physiological disruption that resolves through organism compensation, accelerated drug clearance, or both. Over sustained exposure, it kills: direct antifungal action that reduces organism growth, inhibits hyphal transition, and degrades biofilm (Bahraminia et al., 2024). These are different threats to the organism and would produce different clinical responses.
For CHS patients, this dual mechanism suggests a temporal distinction:
Acute CHS episodes: CBD introduction during an active hyperemetic episode adds a variable to an already unstable system and is unlikely to provide immediate benefit. Stabilization through hydration and caloric loading should take priority.
Maintenance between episodes: CBD at low, carefully spaced doses could theoretically reduce organism burden over time through its direct antifungal action and prevent subsequent CHS cycles. Dose spacing should account for the 18-32 hour half-life. The level of initial response would be expected to correlate with organism density and the degree to which the organism is actively managing host physiology through the ECS interface. CBD has an established safety profile with no attributed deaths, and the acute signaling disruption observed in the longitudinal case study, while subjectively intense, resolved completely within hours. That case represents an extreme colonization density unlikely to be matched in the typical CHS population. The most accurate prediction for CHS patients is some type of response from CBD, the character of which would itself be informative.
VI.IV The Mirror Case: Emetic Suppression as the Inverse of CHS
The longitudinal case study documented in Craddock (2026b) presents a clinical picture that is, in several respects, the inverse of CHS. The case subject uses cannabis therapeutically and does not exhibit cyclical vomiting. Instead, the documented experience over multiple years has been emetic suppression so complete that the subject was unable to trigger vomiting even through manual stimulation of the gag reflex. On multiple occasions during periods of severe nausea, mechanical attempts to induce emesis produced no effective result.
The interpretation within the biochemical computer framework is that both CHS and emetic suppression represent organism-mediated gut management through the same CB1/TRPV1 interface, operating in opposite directions depending on the organism's operational context:
In CHS, sustained THC interference degrades the organism's control of the gut signaling layer. But "system failure" may be too generous a description. The alternative possibility, one that the framework permits, is that the organism has upregulated the host into a potentially fatal feedback loop. In the context of Homo candidus, where the organism and the social group are co-adapted, such a loop would be interrupted by communal intervention: someone would feed the afflicted individual, break the glucose threshold, and terminate the episode. In Homo sapiens, where neither the social infrastructure nor the recognition exists, the loop runs unchecked. The organism may not be "failing" to control emesis. It may be executing a program that was never designed to run without support. CHS is a relatively recent clinical finding, consistent with a response that the organism has not had evolutionary time to refine for the modern context.
In the longitudinal case, the organism maintained tight enough control of gut signaling to lock the emetic reflex entirely. The interpretation offered in the case study is that vomiting became operationally dangerous to the organism: in an advanced colonization state where the organism is managing gut substrate access, electrolyte balance, and circulatory dynamics, a violent emetic event risks electrolyte loss, gut content exposure, and disruption of the substrate access architecture the organism has built. The redacted article described in Redacted Science indicated that in late-stage progression, if the subject did vomit, death would likely follow swiftly from electrolyte loss.
The same interface, the same organism, the same receptor set, producing opposite clinical presentations based on different operational states. CHS is the signal layer overwhelmed. Emetic suppression is the signal layer holding.
VI.V Shared TRPV1 Signature Across Presentations
One observation connects CHS and the longitudinal case study across their otherwise opposite clinical presentations. Throughout the documented course of the longitudinal case, hot showers have been consistently the most reliable source of symptomatic relief, independent of cannabis use status. At peak symptom periods, the case subject showered multiple times per day. The subjective quality of relief was immediate and dramatic regardless of symptom severity, sufficient to produce a noticeable shift in mood and overall wellbeing. On almost every day, even during the worst of it, the subject manages to sing in the shower. "One Last Breath" by Creed is a go-to. Tenor II, high school All-State twice. The shower makes that possible on days when nothing else does. This pattern, compulsive hot shower use providing disproportionate symptomatic relief and a sense of restoration beyond what the physical intervention would normally explain, is the signature clinical feature of CHS.
Its presence in a non-CHS context, in an individual with documented long-term C. albicans colonization but no cyclical vomiting, supports the interpretation that both populations share a common TRPV1-mediated mechanism rooted in organism activity rather than cannabis pharmacology alone. The TRPV1 override is not specific to the CHS disruption state. It is a general feature of organism-mediated autonomic management, observable whenever the organism is modulating host physiology through this receptor interface.
VI.Va Pharmacological Evidence: Drugs That Work and Drugs That Don't
The medications that provide relief in CHS offer additional support for the organism-mediated model, because the drugs that work are not the drugs the standard emesis model would predict.
Ondansetron, a 5-HT3 receptor antagonist and the standard first-line antiemetic for most clinical vomiting, does not work well for CHS. This is documented across multiple case series and acknowledged in clinical guidelines. If CHS were a straightforward emetic pathway dysfunction, the drug that stops most vomiting should stop this vomiting. It does not.
The drugs that do work are notable for where they act:
Haloperidol, a butyrophenone antipsychotic with high-affinity D2 dopamine antagonism, has produced complete symptom resolution in multiple case reports. This is typically attributed to its central antiemetic properties. However, the Gpr1 receptor in C. albicans responds to clozapine, a dopamine receptor antagonist, which inhibits morphogenesis through the Gpa2-coupled cAMP-PKA signaling pathway (Midkiff et al., 2011; see §4.2). Haloperidol may not simply be suppressing the patient's nausea. It may be directly suppressing the organism's hyphal transition through the same dopaminergic interface.
Benzodiazepines (lorazepam, diazepam) provide relief through GABA-A receptor agonism. C. albicans has documented interactions with GABA signaling pathways. The sedative and anxiolytic effects on the patient are well understood, but the drug may also be modulating the organism's behavior through a shared signaling substrate.
NK1 receptor antagonists (aprepitant and related compounds) block the Substance P receptor. Substance P is a neuropeptide, and the organism's ten peptide transporters (§4.1) import host-derived peptides as environmental sensors. If the organism is reading Substance P as an input signal through its peptide transport system, an NK1 blocker cuts off that information stream.
The pattern is consistent. The drugs that work for CHS are the drugs that act on receptor systems the organism interfaces with. The drug that should work based on the standard emesis pathway does not. This is not proof, but it is the pharmacological signature of a condition with an organism component rather than a purely host-mediated receptor dysfunction.
VI.5b Anecdotal Observations from the CHS Patient Community
The CHS patient community, particularly the r/CHSinfo subreddit, provides uncontrolled but directionally useful observations that are consistent with the organism-mediated model and difficult to explain within the standard framework.
Relief from maintaining a full stomach. Multiple patients report that keeping food in their stomach attenuates symptoms. This is consistent with Prediction A (prodromal caloric loading) and with the glucose override mechanism described in §6.2.3. The variability in response across patients, some report significant relief while others do not, is consistent with varying colonization densities: patients with lower organism burden may maintain blood glucose above the Hgt4 threshold with a normal meal, while patients with higher burden may burn through the glucose buffer faster.
Persistent symptoms months after cessation. Some patients report continued nausea, gut dysfunction, and malaise five months or more after complete cannabis cessation, confirmed by negative drug screens. The standard model has difficulty explaining this. Cannabis metabolites, even fat-stored THC, are cleared well within this timeframe. But the organism does not leave when the THC does. Cannabis cessation removes the signal jammer and allows the organism to re-establish equilibrium, which resolves the acute CHS cycle. It does not reduce colonization density. A patient with elevated C. albicans burden will still have organism-mediated gut effects long after the last THC molecule is gone. The persistence of symptoms beyond the pharmacokinetic window of cannabis is itself evidence that something other than THC is contributing to the condition.
Relapse from trace exposure. One patient reported that a single whiff of secondhand THC vape exhale, after months of complete abstinence, triggered a full hyperemetic episode. This is pharmacologically implausible in the standard model. The dose from secondhand vapor is negligible. But if the organism has spent months re-establishing full signaling control during the abstinence period, running the gut at a tightly managed equilibrium, even a trace amount of THC jamming the signal layer may be sufficient to destabilize the system. The organism's grip is tighter after months of uninterrupted management, and its tolerance for interference is correspondingly lower. The sensitivity is not the patient's sensitivity to THC. It is the organism's sensitivity to signal disruption.
Feeling cold. CHS patients frequently describe feeling profoundly cold during episodes. As discussed in §6.2.4, this maps to the glucose mechanism: peripheral vasoconstriction from low blood sugar produces a chill that hot showers directly address. The cold sensation and the nausea are two presentations of the same underlying glucose deficit.
These observations are anecdotal and uncontrolled. They do not constitute evidence. But they are consistent with the framework's predictions and inconsistent with the standard model's explanatory capacity. The patient community is generating observational data that formal research has not yet captured.
VI.Vc Dietary Modification as a Test of the Organism-Mediated Model
This section is not medical advice [I am not a doctor folks. I’m an architect]. It is a proposed grocery test. The logic is simple: if dietary changes that have no antiemetic properties but do have documented antifungal activity against C. albicans produce symptom improvement in CHS patients, the standard pharmacological model has no explanation for the result. These are foods, not drugs. There are no labels to read. They do not act on emetic pathways. They act on a fungus. If they help, the fungus is involved. [History will decide]
The following dietary modifications are based on peer-reviewed evidence of antifungal activity against C. albicans specifically. Each has a documented mechanism. None requires a prescription. [All of them are rather tasty, imo]
Coconut oil. Virgin coconut oil contains medium-chain fatty acids (MCFAs), primarily lauric acid (C12) and caprylic acid (C8), both of which have demonstrated antifungal activity against C. albicans at concentrations comparable to or exceeding standard azole antifungals (Akula et al., 2021, Al-Joubori 2026). Caprylic acid disrupts fungal cell membranes through direct penetration of the lipid bilayer, inhibits hyphal transition, adhesion, and biofilm formation, and shows synergistic effects when combined with other antifungal compounds (Jadhav et al., 2017; Pohl et al., 2011; Yoo et al., 2019). In a murine oral candidiasis model, capric acid (also present in coconut oil) significantly improved symptoms and suppressed mycelial growth on tongue surfaces (Takahashi et al., 2012). Coconut oil is also a source of medium-chain fatty acids that activate GPR84, the immune cell receptor described in the Thaiss et al. vagus nerve signaling pathway queued for §5.5 of this paper. The patient is getting direct antifungal action and immune modulation from the same tablespoon.
A CHS patient who replaces their cooking oil with coconut oil, adds it to coffee or smoothies, or uses it as a fat source in their morning caloric loading protocol (Prediction A) is combining glucose override with antifungal delivery in the same meal. [Also, it goes great in no salt added bone broth]
Cinnamon. Cinnamaldehyde, the primary active compound in cinnamon, has documented antifungal activity against C. albicans including inhibition of biofilm formation and hyphal growth. Ceylon cinnamon (Cinnamomum verum) is preferred over the more common cassia variety for sustained use, as cassia contains higher levels of coumarin, which can stress the liver at high doses. Ceylon is available at most grocery stores and clearly labeled. A patient who adds cinnamon to their morning oatmeal, toast, or coffee is delivering a biofilm disruptor to the organism's home territory with breakfast. [Come on, we all like cinnamon toast]
Garlic. Allicin, the active sulfur compound released when garlic is crushed or chopped, has broad-spectrum antifungal activity including direct activity against C. albicans. Crushing the garlic and letting it sit for a few minutes before cooking maximizes allicin release. Raw is more effective than cooked, as heat degrades allicin, but any garlic is good garlic. The antifungal literature on allicin is extensive and well-established. [Just make sure your significant other has some too]
Oregano oil. Carvacrol and thymol, the primary active compounds in oregano oil, show antifungal synergy with caprylic acid against C. albicans, achieving greater than 6-log reduction (complete eradication) within one minute at body temperature in vitro through combined membrane disruption and efflux pump inhibition (Yoo et al., 2019). This is not a subtle effect. Oregano oil is available as a dietary supplement and as a culinary ingredient. [I have not tried this one, I’m just giving you the science]
Apple cider vinegar. Acetic acid has documented antifungal properties against C. albicans. The acidic environment also disfavors hyphal transition, which is pH-sensitive and favored by neutral-to-alkaline conditions. [I don’t do this one either, you don’t need to do them all]
Iodized Salt (table salt). Iodized salt is documented to have very fast acting anti-fungal properties. If you are using sea salt, switch to iodized salt. It is not recommended to change your actual salt intake. That would invalidate the grocery test.
A Note from The Architect
[Listen up. If you are reading this section and have CHS – you are already a self-medicating individual. So, you need to hear what I say next. These are groceries. There are no labels involved. These are not drugs. These are also not supplements. These are normal, everyday items sold at your grocery story – not some health food store. For example, I bought Coconut Oil at Dollar General.
Supplements are drugs. Period. If you are considering supplements, it would be wise to have someone informed about them advising you or even prescribing them. However, there are some obstacles to that. In 1994, Congress passed a law call the Dietary Supplement Health and Education Act. As usual, the law does exactly the opposite of what the name implies. What it did by making the foods was 1) Reduce education about them for doctors (doctors get a lot of material on prescription drugs because the companies have an incentive to provide it) 2) It created a whole industry of off-the shelf drugs as foods, and 3) discouraged investigation into these alternatives because they are not as profitable.
One example: Lemon balm. Melissa officinalis. It has documented antifungal activity against Candida albicans. It is a clinically effective anxiolytic — head-to-head trials show it performs comparably to benzodiazepines, a $3.5 billion global market. It inhibits acetylcholinesterase — the same mechanism of action as donepezil and the other Alzheimer's drugs that make up a $1.6 billion market segment. And it is itself an antifungal, relevant to the $17 billion antifungal drug market. Three therapeutic categories, over $22 billion in combined annual pharmaceutical sales, and a single herb covers all three. In France, pharmacists dispense it. In the United States, it sits on the supplement shelf next to the melatonin because of a law Congress passed in 1994.
Your doctor will never learn about it. It is not on the decision tree. You do not have access to sufficient research to know about it. So, for purposes of this grocery test, just stay away from these things. Do not assume your Health Food checkout clerk is a good resource.]


The Test
The proposed dietary test for CHS patients is straightforward: change your diet. Whatever else you decide to do about cannabis consumption, whether you cut back, quit, or keep going, add these foods. They are scientifically documented antifungals effective against C. albicans. If the organism is involved in CHS, they should help. If it is not, they are still groceries.
Note: If this theory is correct, you may suffer from candida die off symptoms. These are not pleasant. However, things should eventually improve. This author’s personal recommendation would be to introduce ONE of these things for a period of time, then also introduce another one…followed by another one. This may help avoid more dramatic reactions. Realize, candida is reacting to a system out of balance. What causes that imbalance could just be the THC or it could be something more dramatic. If it is just THC, this regimen should improve the situation. If it is something more dramatic, this regimen may actually help with the CHS, but exacerbate the underlying condition as C. albicans is no longer able to help with the imbalance.
Track symptoms daily: morning nausea severity, frequency of hyperemetic episodes, shower frequency and duration, and overall gut comfort.
Here is a list of simple grocery changes (once again, moderation is recommended):
• Add virgin coconut oil as a daily fat source.
• Add Ceylon cinnamon to morning meals.
• Include crushed garlic in at least one meal per day.
• Optionally add oregano oil as a supplement or culinary ingredient. [Add some spice to your life]
If these dietary additions produce measurable symptom reduction over two to four weeks, the standard model, which attributes CHS entirely to THC receptor dynamics, has difficulty accounting for the improvement. These foods do not modulate CB1 receptors. They do not activate TRPV1. They do not alter THC metabolism. What they do is suppress C. albicans growth, inhibit its transition from yeast to hyphal form, degrade its biofilms, and disrupt its cell membranes. If that helps, the organism is part of the problem.
Conversely, if progressively adding these to your grocery list and diet produces no change in CHS symptoms, that is useful negative data that weakens the organism-mediated model for this particular application.
This test costs less than a trip to the emergency department. It risks nothing. Every ingredient is available at a grocery store. And unlike cannabis cessation, which asks the patient to give up something they may depend on medically, this test asks them only to change what they eat alongside it.
For the patient who wakes up nauseated: eat in the morning. Candida albicans gets more aggressive when blood sugar is low. What you eat in the morning is your call, but a morning meal will set you up for a higher blood glucose level, which, if the theory is correct, would reduce the severity of the afternoon reaction. Additionally, if the framework is right, the day goes better. If it is wrong, you had a decent breakfast.
Next, track your diet and your symptoms. This is invaluable for your health professional and you. If symptoms fluctuate with diet, that is something that no one is addressing, regardless of what items are consumed.
Finally, once you have a baseline recorded, slowly begin introducing one of these items to your diet. If nothing changes, no harm no foul. If things get worse, that is something just important to note as if things get better. If they do get worse, you will have to decide – do you continue that diet, or revert back to your baseline diet. From experience, candida sufferers that achieve resolution through medicinal methods are very familiar with a die-off period where things feel worse. According to this model, that is likely to be multiple effects. When candida die, they release toxins and electrolytes. These can effect your system. Additionally, according to this model, the organism is already directly communicating with parts of your system. When this communication stops, your system will have to recalibrate. Neither of these is an overnight process.
To review, this is a grocery test and a documentation test. One without the other is not a good plan. It will require both. According to this model, you are already running this experiment, you just are not documenting it.
VI.VI Testable Predictions
The following predictions are designed to validate or falsify the proposed C. albicans contribution to CHS. Each isolates a variable that the standard pharmacological model does not address. Confirmation of even one would establish a connection warranting further investigation. Failure across all predictions would indicate that the framework does not extend to this syndrome.
The predictions are ordered from simplest and least expensive to most complex, beginning with interventions that require no specialized equipment, institutional approval, or laboratory analysis.
Prediction A (Prodromal Caloric Loading). CHS patients in the prodromal phase who eat immediately and aggressively upon waking, beginning with rapid-absorbing carbohydrates followed by sustained protein and fat sources, will experience reduced frequency and severity of morning nausea and decreased progression to the hyperemetic phase. The proposed mechanism is straightforward: caloric loading raises blood glucose above the Hgt4 threshold (~5 mM) before the organism's fasting-state operational shift can escalate to emetic destabilization. This intervention requires no prescription, no clinical supervision, and no cost beyond the meal itself. A patient who wakes nauseated and eats a substantial breakfast within the first thirty minutes, rather than avoiding food or retreating to the shower, is performing the most basic test of the glucose override hypothesis. If morning caloric loading reliably attenuates prodromal symptoms, the glucose mechanism gains immediate clinical support.
Prediction B (Glucose Administration in Acute Episodes). Intravenous dextrose administration during an active hyperemetic CHS episode will attenuate the episode more effectively than isotonic saline alone, independent of antiemetic medications, by raising blood glucose above the organism's Hgt4 calibration threshold and signaling a return to commensal operational mode. Method: prospective emergency department protocol comparing IV dextrose to standard IV saline resuscitation in presenting CHS patients, with time-to-symptom-resolution as the primary endpoint. CHS patients frequently present with dehydration, and IV dextrose is not standard first-line treatment. If dextrose produces faster resolution than equivalent-volume saline, the glucose mechanism is supported over simple rehydration.[Please don’t try this at home]
Prediction C (Colonization Density). CHS patients will exhibit higher gut C. albicans colonization than matched heavy cannabis users who have never developed CHS. However, the appropriate measurement method is not straightforward. Stool PCR, the standard and least invasive quantification method, measures what the organism is shedding into the gut lumen. It does not measure what is embedded in the tissue. C. albicans invades submucosally through hyphal penetration, forms biofilms on and within mucosal surfaces, and its entire architectural strategy in this framework is tissue-level integration rather than luminal presence. A patient with aggressive submucosal colonization and minimal luminal shedding could return a low stool PCR result and appear uncolonized when they are not. Before stool PCR can be trusted as a screening tool for this prediction, a validation study comparing stool PCR quantification to mucosal biopsy with fungal staining (PAS or GMS) in the same patients is needed to determine whether stool shedding reliably correlates with tissue-level colonization density. Without that validation, a negative stool PCR result does not falsify the prediction. It may simply mean the screen is looking in the wrong compartment.
Prediction D (Arachidonic Acid Metabolite Signature). CHS patients will show an arachidonic acid metabolite profile consistent with substrate competition: elevated PGE₂ with depressed anandamide and 2-AG levels, compared to matched heavy users without CHS. Method: plasma or intestinal tissue measurement of PGE₂, AEA, and 2-AG concentrations. This tests the substrate competition mechanism described in VI.II.II directly.
Prediction E (Antifungal Resolution). Targeted gut antifungal treatment will resolve or significantly attenuate CHS in patients who continue cannabis use. This is the strongest differentiating test. If CHS resolves without cannabis cessation after antifungal treatment, the standard model in which THC itself is the sole cause cannot account for the result. Method: clinical pilot with targeted oral antifungals (e.g., fluconazole, nystatin) in CHS patients who decline or are unable to achieve cannabis cessation, with symptom tracking and stool C. albicans quantification pre- and post-treatment.
Prediction F (Gut CB1 Receptor Maintenance). C. albicans colonization prevents gut CB1 receptor downregulation under chronic THC exposure. Method: in vitro intestinal epithelial cell cultures with and without C. albicans colonization, exposed to chronic THC, with CB1 receptor density measured over time. A germ-free mouse model (colonized vs. non-colonized, chronic THC, gut and brain CB1 density compared) would provide in vivo confirmation. A third arm, colonized mice receiving antifungal treatment, would test whether removing the organism allows normal downregulation to proceed.
Prediction G (CBD Response). CHS patients who introduce CBD alongside continued THC use will show a clinical response. At the colonization densities expected in this population, the response may present as a single gradual improvement consistent with direct antifungal burden reduction (Bahraminia et al., 2024), or it may exhibit two phases: a brief initial disruption from signaling interference followed by longer-term improvement from organism reduction. Whether the acute signaling disruption observed in the longitudinal case study (§6.3) is detectable at lower colonization densities is an open question. Any measurable response to CBD in CHS patients, positive or negative, would support the organism-mediated model over the standard pharmacological model, which has no reason to predict that CBD should affect CHS at all. Method: prospective cohort with stool PCR at baseline, symptom diary, and standard CBD dosing protocol. [This one is kinda like a wildcat well, except no high upfront cost.]
Prediction H (Transcriptomic Immune Signature). Building on the findings of GSE303922, CHS patients' gut immune activation profile (B-cell immunoglobulin upregulation, impaired barrier function, elevated IgE) will correlate with C. albicans colonization density rather than with THC exposure levels. Matched heavy cannabis users without CHS should show neither the immune activation nor the elevated colonization. Method: paired transcriptomic and mycobiome analysis in a case-control design.
6.7 Positioning and Limitations
The connection presented here between C. albicans and cannabinoid hyperemesis syndrome is novel and should be treated accordingly: as a potential linkage derived from the biochemical computer framework architected from synthesis of research, not as an established causal relationship.
The argument is theoretical but not unsupported. The 2025 transcriptomic study (GSE303922) independently found an immune activation profile in CHS patients consistent with C. albicans colonization, while simultaneously finding no ECS transcript changes, exactly the pattern the organism-mediated model predicts and the standard model does not. The pharmacological evidence is similarly consistent: the drugs that work for CHS (haloperidol, benzodiazepines, NK1 antagonists) act on receptor systems the organism interfaces with, while the standard antiemetic (ondansetron) that should work based on the conventional emesis model does not.
The framework generates predictions that are testable, falsifiable, and in several cases inexpensive to pursue. The first prediction, caloric loading in prodromal patients, can be tested by any individual experiencing morning CHS symptoms, with no institutional infrastructure required.
Several limitations apply. The substrate competition model assumes that fungal burden in CHS patients is sufficient to meaningfully deplete the arachidonic acid pool available for endocannabinoid synthesis. This is an empirical question. The Hgt4 glucose threshold connection is mechanistically plausible but has not been tested in a CHS context. The mirror case comparison between CHS and emetic suppression, while conceptually clean, relies on a single longitudinal case study and should not be generalized without additional cases. The palliative trap hypothesis (that hot shower relief delays caloric intervention) is observationally consistent with clinical descriptions but has not been directly tested. The pharmacological observations regarding haloperidol, benzodiazepines, and NK1 antagonists are drawn from case reports and anecdotal accounts rather than controlled trials, and alternative explanations for their efficacy exist within the standard model.
The clinical implication, if validated, would be a reframing: CHS shifts from a cannabis toxicity syndrome requiring abstinence to a host-organism interface disruption syndrome amenable to antifungal, metabolic, and dietary intervention. Cannabis cessation would still resolve symptoms (by removing the signal jammer and allowing the organism to restore its signaling equilibrium), but it would no longer be the only therapeutic option. This would be relevant to the growing population of patients who use cannabis for other medical conditions and face a difficult choice between CHS management and loss of therapeutic benefit.
The tests come first. The reframing follows only if they succeed. [Tick-Tock, next block]
 6. The Evolutionary Trinity:Three Co-Evolving Components
The Saline Oscillation Hypothesis proposes that the full coevolutionary architecture required three simultaneously reinforcing components, a “trinity”:
The fungal symbiont, operating through the ECS and the expanded control surface described in Section 5 to modulate host physiology, perfusion, electrolyte balance, and cognition
Host physiology, including the cardiac suction mechanism, IVC dynamics, ECS interface, and Na⁺/K⁺-ATPase architecture
Cooperative social structure, initiated by communal phytocannabinoid use promoting peaceful bonding, later formalized through language-enabled elder care and pharmacological support
Two of these legs, the symbiont (present as a commensal) and the social structure (initiated by the cannabinoid flywheel), were established before the salinity oscillations began. Language did not create the trinity. Language completed the trinity, and allowed it to accelerate.
6.1 The Saline Oscillation Forge Theory
Two independent lines of recent evolutionary biology research support this paper's argument that the partnership architecture is a maintained state rather than a default state. Song, Chen, Shen, & Zhang (2025) established that beneficial mutations are far more abundant than the Neutral Theory of Molecular Evolution assumed, but rarely fix because environments change before fixation can occur — natural populations continuously chase moving environmental targets. Barnett, Meister, & Rainey (2025) experimentally demonstrated that under cycling-environment selection, lineages evolve localized hypermutability biased toward generating adaptive variation at specific loci. The two findings together establish that lineages with the right architecture maintain partnership-relevant functions across environmental cycling.
This paper proposes a further architectural consequence: the EARS-scenario saline oscillation cycled for hundreds of thousands of years within a range the partnership architecture was selected to track, alternating between freshwater and hypersaline extremes through a structure of sustained selective pressure followed by rapid transition. This cycling regime functions structurally as a forge (Figure A). 
A forge transforms metal not in a single step, but through repeated cycles: the metal is heated until it becomes workable, hammered into a new form, then quenched or cooled to lock that form in place before the process begins again. Each cycle does specific work. Heat opens the structure, shaping forces it into a new configuration, and cooling preserves the change so the metal does not simply return to what it was. In this paper, the saline oscillation is analogous to that process: sustained environmental phases do the heating and working, rapid transitions do the quenching, and over many cycles the host-organism partnership is not merely selected, but forged into a deeper, more durable architecture.

 
The forge metaphor is not novel as evolutionary mechanism — mainstream evolutionary biology already accepts that cycling environments shape genome architecture in ways that stable environments do not, that alternating selective regimes produce more robust adaptation than constant pressure, and that the work done by selection during specific cycle phases shapes the resulting architecture in specific ways. 
The framework's contribution is extending this accepted principle to its full implication for coevolutionary partnerships rather than for single-lineage adaptation. Each EARS oscillation cycle does specific work on the partnership architecture: sustained selection within a configuration deepens the integration; rapid transition locks new configurations in place; the next sustained phase deepens integration of the new configuration without permitting the prior integration to relax to neutral. Over many cycles across hundreds of thousands of years, the partnership architecture becomes forged at the structural level — not merely selected, but shaped by the specific molecular interfaces between host and organism across each cycle's selective regime.
Two implications follow directly. First, the partnership architecture present in modern Homo sapiens cannot have been built by substituting C. albicans for an earlier partnership organism at any point in the lineage's history; forge-level integration requires the same molecular interfaces operating across the cycling history. The pan-mammalian observation that each mammalian lineage carries its own lineage-specific Saccharomycetaceae symbiont (Craddock, Pan-Mammalian) reflects this constraint — each host-organism pairing was forged together from early in the lineage's evolutionary history. Second, the disruption signatures observed when modern pharmacology removes partnership components (Lionakis et al., 2008; Lionakis section in Kemper et al., 2023) are predicted by forge-level integration: the architecture cannot be unforged without disruption proportional to the depth at which the partnership has been integrated into host physiology. [This partnership is not optional]
The framework's prediction that the forge process produces deeper architectural integration than ordinary selection has a worked example within the Candida genus itself. C. albicans is documented across the mycology literature as having the most structurally and behaviorally complex molecular repertoire of any pathogenic Candida species: the most elaborate morphological state-space, the largest secreted aspartyl protease family, the most diverse adhesin and immunomodulatory cell wall component repertoires, the most developed biofilm-forming and complement evasion machinery, and the most extensive candidalysin/ECE1 system. Sister species including C. dubliniensis, C. glabrata, C. tropicalis, and others show substantially reduced complements of this architectural machinery. The mainstream framing treats this complexity differential as C. albicans has more virulence factors than its sister species,' but the framing has a problem the field has not adequately addressed: virulence factors should be costly to maintain when not actively producing pathogenesis, and natural selection should have pruned the elaborate machinery toward whatever subset is consistently advantageous. The persistence and continuous refinement of C. albicans's elaborate architecture across evolutionary time is inconsistent with the standard opportunism narrative. The forge model resolves this: C. albicans's elaborate machinery is not a collection of retained virulence factors but the partnership architecture that the EARS-scenario forge specifically produced. The complexity gradient across the Candida genus tracks the gradient of coevolutionary exposure intensity — C. albicans was the species in the forge, sister species were not, and the documented architectural complexity differential is what the forge model predicts the outcome should look like.
6.2 Language and the Transmission of Late-Stage Cognitive Enhancement
The ECS modulates neuroplasticity, pain perception, and cognitive function (Di Marzo and Piscitelli, 2015). Late-stage symbiont activity produces pain-free windows concurrent with enhanced cognitive clarity and creative drive. This is documented both in the historical cohort (Craddock, Redacted Science) and consistent with known CB1-mediated neurological effects.
In pre-linguistic hominids, this late-stage cognitive enhancement had limited transmission bandwidth. Tool-making demonstrations, gestural communication, and behavioral imitation could transmit some knowledge as evidenced by the Lomekwi tools (3.3 Ma) predating any evidence of language. However, the abstract, strategic, and philosophical content documented in the historical cohort (where common Everyman subjects in the final stages discussed deeply complex topics with extraordinary clarity) requires symbolic language for transmission. Language did not create the survival value of late-stage clarity; it amplified it by orders of magnitude.
With the emergence of language, for which Homo habilis (KNM ER 1813, ~1.9 Ma) shows an enlarged Broca’s area visible in the cranium, and for which the endocast of KNM-WT 15000 (Homo erectus, ~1.6 Ma) shows Broca’s area asymmetry (Walker and Leakey, 1993; Turkana Basin Institute, 2021), the lucid elder could articulate insights, strategies, and knowledge with full symbolic complexity. The social group that protected its elders during late-stage decline received this transmission; groups that discarded the weak lost it.
This creates a three-way selection pressure: the symbiont benefits from extended host survival (longer cycle completion); the host’s social group benefits from the elder’s clarity; and the social structure itself is reinforced by the value of what the elder produces. Language is the accelerant that transforms a modest survival advantage into a civilizational engine.
6.3 Evidence from the Fossil Record
Species	Date	Location	Relevant Feature
A. afarensis (Lucy)	~3.2 Ma	Afar Triangle	Bipedal, social groups, freshwater lakes, cannabinoid flywheel plausibly active
Lomekwi Tools	~3.3 Ma	Lake Turkana	Cognitive sophistication predating Homo, same salt basin
H. habilis	~1.9 Ma	East Africa	Enlarged Broca’s area, proto-language capacity
P. boisei	~1.75 Ma	Olduvai/Natron	Dietary specialist, evolutionary dead end
H. erectus (Turkana Boy)	~1.6 Ma	Lake Turkana	Broca’s area asymmetry, long-distance running, cooperative hunting, periodic saline lakes
First dispersal	~1.5 Ma	Out of Africa	Trinity-equipped species carrying symbiont to new environments
 
Figure 2 The Critical Window (3.3-1.3 Ma)
Convergence of environvmental, biological, and coevolutionary evidence
 
7. Archaeological Evidence for the Cannabinoid Flywheel
7.1 Ritual Cannabis Use in Mortuary Contexts
The earliest scientifically verified evidence for psychoactive cannabis use comes from the Jirzankal Cemetery (~500 BCE) in the eastern Pamirs, where chemical analysis of wooden braziers from mortuary contexts revealed cannabinoid residues with unusually high THC levels (Ren et al., 2019). The cannabis was burned on heated stones in enclosed spaces during funerary ceremonies, a ritual context directly associated with death and transition. At the Yanghai tombs (~500 BCE, Turpan), a leather basket and wooden bowl filled with cannabis seeds, leaves, and shoots were found near the head and feet of a deceased individual identified as a probable high-ranking shaman (Russo et al., 2008). The Jiayi Cemetery (~800–400 BCE, also Turpan) yielded a burial shroud composed of 13 intact desiccated cannabis plants arranged over the body (Jiang et al., 2016).
The consistent association of cannabis with mortuary ritual, shamanic figures, and funerary ceremony across multiple independent sites is precisely the pattern predicted by the trinity model: the plant that served the dying elder becomes sacred, and its administration becomes the province of the specialist who tends the elder, the shaman. The shaman’s role is not mystical invention; it is the social expression of the group member who manages the elder’s pharmacological support during transition.
Herodotus, writing in the fifth century BCE, described Scythian funerary practices involving cannabis vapor inhalation, an account subsequently corroborated by archaeological finds at Pazyryk (~2,400–2,500 years BP), where cannabis seeds, censers, and hempen clothing were recovered from burial mounds (Rudenko, 1970; Ren et al., 2019).
7.2 The Pharmacological Argument for Cultivation Priority
The eight Neolithic “founder crops” (emmer wheat, einkorn wheat, barley, lentils, peas, chickpeas, bitter vetch, and flax) were domesticated in the Fertile Crescent between approximately 10,500 and 7,500 years ago (Zohary and Hopf, 1988; Zohary et al., 2012). These are caloric and industrial crops. Cannabis, however, offers something no grain provides: direct modulation of the mammalian ECS. Cannabis sativa is among the oldest cultivated plants in the world, with dried specimens from the Oki Islands of Japan dating to approximately 8000 BC (Crawford, 2006) and cultivation in East Asia from at least 4000 BC (Li, 1974; McPartland et al., 2019).
We propose that the motivation to cultivate a psychoactive plant may have preceded or paralleled the motivation to cultivate caloric crops. A group whose social cohesion depends on a plant, first for communal bonding, later for elder care during transition, has an immediate, non-deferrable need to secure its supply. Grain can be foraged; the medicine that holds the group together cannot be left to chance.
7.3 Endogenous Cannabinoids, Running, and the Rift Valley
Between transition phases, endogenous cannabinoids are elevated by sustained physical activity. The “runner’s high” is mediated by anandamide and 2-AG, not endorphins as previously assumed (Fuss et al., 2015). For hominids in the EARS environment, long-distance running (needed for persistence hunting, foraging range expansion, possibly communal communication, and predator avoidance) served as the primary endogenous ECS maintenance strategy.
This observation generates a testable prediction with contemporary resonance. The Kalenjin people of Kenya’s Rift Valley, the geographic heart of the EARS, adjacent to the Turkana Basin, produce a wildly disproportionate share of the world’s elite distance runners. Standard explanations invoke altitude training effects, lean body habitus, and cultural emphasis on running. The Saline Oscillation Hypothesis adds a complementary explanation: these populations are the direct descendants of hominids for whom long-distance running was not merely athletic but pharmacological and the primary mechanism for maintaining endogenous ECS tone in the environment where the coevolutionary program was deepest.
________________________________________
8. The Cardiac Architecture Hypothesis: Developmental Preservation and the Breaking the Trinity
8.1 The Mammalian Default: Suction Dominant Circulation at Birth
The mechanistic sequence described in Section 4 operates on standard mammalian cardiac hardware. No novel anatomy is required to initiate or sustain the program. What distinguishes Homo candidus is the symbiont's management of the existing cardiovascular architecture through ECS signaling. The question that has persisted throughout this framework — when and how did the cardiac architecture shifts from suction-dominant to pump-dominant — may be resolved by a developmental observation rather than an evolutionary one: every mammal is born with a suction-dominant heart.
Neonatal cardiac physiology is fundamentally different from adult cardiac physiology. The fetal and neonatal heart operates with open foramen ovale, patent ductus arteriosus, and diastolic mechanics in which the suction contribution to ventricular filling is proportionally greater than in the mature adult heart. The transition from fetal to adult circulatory dynamics, involving closure of the foramen ovale, involution of the ductus arteriosus, and progressive shift toward systolic ejection as the dominant filling mechanism, is a normal developmental process that occurs over the weeks and months following birth, with cardiac remodeling continuing throughout postnatal maturation.
The pump-dominant adult heart is therefore not a mutation. It is the developmental endpoint. The suction-dominant neonatal heart is the starting condition. The question is not "when did a genetic shift produce the pump-dominant heart?" The question is "what, in the ancestral context, prevented the normal developmental transition from completing?"
The same principle applies to the pituitary. The neonatal pituitary operates at high activity by default. It manages explosive growth, organogenesis, neurological development, and the establishment of endocrine axes that will govern the organism for its entire lifespan. The "overclocked" pituitary described in the coevolutionary framework is not an upgrade installed by the symbiont. It is the factory setting. Every infant has one. The developmental program progressively reduces pituitary output as growth decelerates and the endocrine system matures. In the adult, the pituitary operates at a fraction of its neonatal capacity at more of a maintenance level, The adult capacity is sufficient for maintenance, but insufficient for the demands of the symbiont's full program.
8.2 The Preservation Mechanism: Why the Ancestral Transition Did Not Complete
We propose that in the ancestral Rift Valley context, the symbiont's role was not to build a suction-dominant heart or to overclock the pituitary. It was to prevent the normal developmental transition that would wind both systems down. The organism preserved the neonatal configuration into adulthood by maintaining ECS-mediated signaling on cardiac conduction and pituitary perfusion during the critical developmental window when the transition would otherwise occur.
The molecular plausibility of this preservation mechanism is supported by the finding that farnesol, the primary C. albicans effector molecule, is a confirmed inhibitor of N-type voltage-gated Ca²⁺ channels in mammalian cells (Roullet et al., 1999) and is present in the human brain at measurable concentrations. Calcium channel activity is fundamental to cardiac conduction and to the developmental remodeling of cardiac electrophysiology. An organism whose primary signaling molecule modulates the ion channels governing cardiac rhythm has the molecular tools to influence whether and when the postnatal cardiac transition completes. CB1 receptors, expressed on cardiac tissue, provide an additional direct pathway through which ECS-mediated signaling could maintain the diastolic suction contribution that the normal developmental program would reduce.
Pituitary preservation operates through the perfusion governance described in Section 4.3 and the ECS-mediated pituitary signaling described in Section 5.7. CB1 receptors on pituitary cells modulate hormone secretion across all axes (Pagotto et al., 2006). An organism managing pituitary perfusion and signaling from birth arrives through breastfeeding into a system where the ECS boot sequence (CB1-mediated suckling reflex) is already active, and has continuous access to the gland during the developmental window when its activity would normally decline. The preservation is not a single intervention. It is continuous management, from neonatal colonization through postnatal development, maintaining the high-activity pituitary state by preventing the downregulation the developmental program would otherwise execute.
The developmental preservation model requires only documented neonatal cardiac physiology, documented postnatal cardiac remodeling, and the documented molecular tools the symbiont possesses to influence both. The transition is not a mystery. It is the default. The mystery was always why it didn't happen in the ancestral population and the answer is that the symbiont prevented it.
8.3 The Three-Key Activation Model: Why Modern Infants Do Not Preserve
If every mammal is born with the suction-dominant heart and the active pituitary, and if the symbiont arrives through breastfeeding in nearly all humans, the question becomes: why does the developmental preservation not occur in modern infants?
The answer lies in the activation requirements for the preservation program. The symbiont's arrival is necessary but not sufficient. The program that prevents the developmental transition requires environmental conditions that are no longer present.
We propose a three-key activation model:
The first key is the symbiont's presence during the critical developmental window. C. albicans is transmitted vertically from mother to child through birth canal transit and breastfeeding (Kumamoto, 2011; Ost and Round, 2023). The CB1-mediated suckling reflex, the first mammalian survival behavior, is the ECS boot sequence through which the symbiont arrives and initial colonization is established. This key is present in virtually all modern infants. The organism arrives. Colonization begins.
The second key is colonization density sufficient to produce meaningful signaling output during the developmental window. This is variable. The output is dependent on maternal colonization depth, breastfeeding duration, early immune development, and the infant's own microbiome ecology. Some infants may achieve deep colonization rapidly. Others do not. In the ancestral context, where antibiotic exposure did not exist, mucosal barrier disruption from processed foods did not occur, and breastfeeding duration was extended, deeper and earlier colonization would have been the norm. This key was more consistently present in the ancestral population than in the modern one, but it is not categorically absent today.
The third key is the electrolyte environment. The saline oscillation, cyclical exposure to elevated and depleted electrolyte concentrations that constitutes the central mechanism of this paper, provided the environmental activation signal. The SIADH-type electrolyte disruption during freshwater transitions following saline acclimation created the physiological conditions under which the symbiont's perfusion management program gained decisive selective advantage. Without this electrolyte signal, the symbiont colonizes commensally, feeds on dietary glucose, performs its baseline maintenance functions, but the preservation program that would prevent the cardiac and pituitary developmental transition does not activate. The program requires the environmental context it was selected within.
Modern infants have the first key universally. Some have the second key to varying degrees. None have the third key. The developmental transition proceeds on schedule because the environmental trigger that would activate the preservation program does not exist in a world of stable, treated drinking water with consistent electrolyte content.
In the ancestral East African Rift Valley, all three keys were present simultaneously. The symbiont arrived through breastfeeding from a mother whose own electrolyte status reflected the saline-oscillating water sources. The infant's developing system was exposed to electrolyte variations from birth through breast milk composition, through early introduction of local water sources, and through the same environmental pressures acting on the entire social group. Colonization established during the critical window. The electrolyte signal was continuous. The preservation program activated, and the suction-dominant heart and high-activity pituitary were maintained into adulthood. The organism did not build Homo candidus. It prevented the developmental transition that would have produced an ordinary adult.
This model also explains the evolutionary trajectory of the phenotype across time and geography. In the earliest stages of the coevolutionary relationship, preservation of the neonatal cardiac and pituitary architecture carried no disadvantage. An infant whose suction heart and active pituitary were maintained into adulthood would exhibit superior perfusion, superior endurance, enhanced crisis tolerance, and better cognitive performance with no transitional decline phases, because the program had not yet evolved the complex multi-phase sequence documented in the redacted source article and the longitudinal case study. That sequence is the product of hundreds of thousands of years of oscillation-driven refinement. The early program was simpler: basic perfusion management and electrolyte handling, the core functions the saline oscillation selected for. Preserved individuals in this early period dominated selection. They were better at everything.
In a Rift Valley population where all three keys were consistently present: 1) universal symbiont transmission through breastfeeding with deep colonization supported by extended nursing, 2) the absence of antibiotics, and 3) continuous electrolyte oscillation from the lake systems, preservation would have trended toward universality. Selection pressure ran hard in one direction: preserve the heart, maintain the pituitary, outperform everyone who doesn't.
As the oscillation cycles ratcheted the coevolutionary relationship deeper over millions of years (Section 4.1), the program became more sophisticated. More phases emerged. More organ systems became involved. More metabolic transitions developed. Eventually, the decline phases appeared. These are the transitional vulnerability periods documented in the redacted source article and in the longitudinal case study (Craddock, Redacted Science). Only at this stage did the evolutionary trade-off described in Section 4.3 materialize: enhanced capability between transitions, increased vulnerability during them. Only now did the social support structure become necessary to protect the individual during difficult phases. Only now did the trinity's third leg, that of cooperative social structure, reinforced by the cannabinoid flywheel described in Section 3, gain its full adaptive value. The trinity did not form because the program was dangerous from the start. It formed because the program deepened until it required social support to sustain.
The spectrum of preservation outcomes with some individuals fully preserved, some partially, some not at all emerged late in the coevolutionary timeline, driven by two factors. First, as the program deepened, the metabolic and physiological demands of the preservation sequence increased, raising the threshold of colonization density and electrolyte exposure required for full activation. Second, and more significantly, the first dispersal out of Africa (~1.5 Ma) carried the population into environments where the third key, the saline oscillation, was weaker or absent. The further from the Rift Valley, the less consistent the electrolyte signal, the less reliable the preservation. Populations at the geographic margins of the dispersal experienced partial or inconsistent activation. The developmental transition began completing in some individuals. Pump-dominant adults appeared — not through mutation but through the absence of the environmental signal that had prevented the transition in the ancestral core zone.
VIII.III Intellectual Growth and Religion in Homo Candidus
[Boom! Hi All, glad to be back. Here is a V4 section on Homo Candidus and religion]
The program described in this section demands more than symbiont presence and environmental exposure. It demands sustained behavioral compliance from the host. Dietary restriction during specific phases. Fluid management under conditions where the body's signals are misleading. Endurance of significant pain without seeking the palliative interventions that would interrupt the process: the hot shower, the emetic, the fast that empties the gut, the instinct to stop eating when eating is exactly what the program requires (Section 7). These are not behaviors that emerge from instinct. They are counterinstinctive. The host must override immediate physiological signals on the authority of transmitted knowledge, doing what feels wrong because someone who survived the process before said it was necessary. [I choose Normal – it looks normal but it is persistence and perseverance through some trying times]
This implies a social infrastructure far more structured than communal bonding. It requires a transmitted protocol: specific behavioral instructions indexed to recognizable phases of the process. It requires authority: individuals whose experience confers the credibility to override another person's instinctive responses during crisis. It requires enforcement: social mechanisms that hold the individual to the protocol when their own will fails. And it requires consequences: the noncompliant individual who seeks palliative relief, abandons dietary discipline, or refuses to endure a transition phase does not merely fall behind. They die. The program, once activated beyond a certain depth, does not accommodate deviation gracefully.
This is natural selection for institutional compliance. The individuals who could not submit to transmitted authority, could not delay gratification across phases lasting weeks or months, could not endure discomfort without seeking immediate relief, or decided to stop eating because of the pain or nausea were removed from the gene pool not by predators or climate but by the program itself. The individuals who could follow instructions, trust the elder's protocol when every somatic signal said otherwise, and maintain discipline across the full arc of the process survived, reproduced, and transmitted both the genetic predisposition for compliance and the cultural knowledge that made compliance productive. The capacity for faith, understood not as belief in the supernatural but as trust in a process whose logic is not immediately apparent to the person undergoing it, was selected for directly by the demands of the program. [Probably not a progressive and tolerant bunch of ancestors]
Critically, neither partner in this coevolution began with a map of the path ahead. The organism did not arrive with a prewritten program for managing host perfusion through a multi-phase physiological transformation. The host did not arrive with knowledge of what the organism would require. Both were learning simultaneously. Each oscillation cycle was a joint experiment conducted across the boundary between two kingdoms. On the organism's side, the biochemical computer tested regulatory configurations, chromatin states, signaling outputs, metabolic adjustments, exploring the solution space through the bet hedging architecture described in Section 5.8. Configurations that kept the host alive longer were epigenetically reinforced and propagated to the next generation of the organism's population within the host. Configurations that failed died with the host. On the host's side, the elder who survived one step further than the previous generation's elder observed what happened and transmitted that observation. Eat when the pain comes. Do not drink when you feel thirsty. Lie down when the pressure builds. Do not seek the hot water. Each behavioral instruction was a data point purchased with a lifetime. And elders, they were worshipped for their intellects. This was a group whose survival depended on the knowledge of the elders.
Notably, over time, this preselects greatly for intelligence and compliance during specific phases but also demands initiative, observation, problem-solving, and leadership from the elders who develop and transmit the protocol. The host must be disciplined, learned, and devout. This selection is made every generation for more than 21,000 years. That’s just one oscillation cycle. [Uno!] The first group was likely a small tribe. The tribe prospered, dominating due to increased hormones from the effect of the suction heart. It grew smarter and more disciplined. [Not what we have going on in most places these days, huh? Seems like we are self-selecting out of the gene pool]
The path was not discovered. It was built, one lifetime at a time, from both directions. The organism wrote the program through chromatin-encoded trial and error, locking in successful signaling configurations across thousands of host generations. The host wrote the protocol through cultural transmission, locking in successful behavioral responses across the same timescale. Neither could have produced the result alone. The organism without a compliant host cannot complete phases that require behavioral cooperation. The host without a sufficiently refined organism cannot survive the physiological demands of the deeper phases. The convergence of both learning curves, biological and cultural, across hundreds of thousands of oscillation cycles, is what produced the Homo candidus phenotype. We have no modern analogue for the depth of this coevolutionary investment. The closest approximation is that every successful transit of the program by every host-organism pair across the entire Plio-Pleistocene contributed one data point to a collaborative solution that neither partner could see the end of.
The devotion is not human or microbial. It is the accumulated weight of millions of lifetimes that each went one step further than the last.
VIII.IV The Generational and Civilizational Math
If we use the full 2.7 Myr window and a 30-year generation time: 
2,700,000 / 30 = 90,000 generations

If even a small population of 500-1,000 individuals per generation is running the program: 90,000 × 500 = 45 million individual lifetimes (conservative) 
90,000 × 1,000 = 90 million individual lifetimes (more realistic)

If you count only the three variability packets (~600,000 years of intense oscillation): 
600,000 / 30 = 20,000 generations 20,000 × 500 = 10 million individual lifetimes

For a frame of reference, it has been roughly 40 generations since the formation of Christianity.

The institutionalization of the host-side protocol was not optional. Individual willpower varies across any population. A process that kills the noncompliant cannot depend on individual willpower alone if the population is to sustain itself across generations. It requires rules that apply universally within the group, designated individuals responsible for enforcement, and social costs for deviation that exceed the immediate discomfort of compliance. It requires, in short, the foundational architecture of organized religion: prescribed behaviors indexed to life phases, authority figures who have undergone the process themselves, communal rituals that reinforce group commitment, and an explanatory framework that gives meaning to suffering. The third leg of the evolutionary trinity is not community. It is civilization with rules. The program required it, and the populations that built it survived. The ones that did not are not represented in the modern genome.[Well, until lately, that is…currently the Overton Window is non-existent]
8.4 Hypophyseal Failure: The Endpoint of Unresolved Preservation
In the ancestral context where all three keys were present, the preserved pituitary operated within a system designed to support it. The saline oscillation provided continuous electrolyte substrate, the social structure supplied dietary and pharmacological support, and the program proceeded through its phases toward completion. The pituitary ran at elevated capacity because the program demanded it, and the program's completion allowed the system to reach its intended endpoint.
In a modern host where the program activates but cannot complete, either because the cardiac architecture has transitioned past the suction threshold (the population at large) or because the activation occurred iatrogenically without the ancestral support structure (the longitudinal case study), the pituitary operates beyond its optimal range indefinitely. The resulting condition resembles prolonged operation of a regulatory system beyond its optimal range: a strategy that may preserve short-term functional performance while progressively reducing long-term adaptive reserve.
This is what the archaic clinical literature termed “hypophyseal failure.” not a disease of the pituitary but the exhaustion of a gland running a program it was not designed to sustain without resolution. The pituitary does not fail because it is defective. It fails because the program it is executing has no endpoint in the modern context. The conversion sequence stalls. The pituitary continues to drive perfusion and endocrine management at elevated capacity. The adaptive reserve depletes. The gland's functional output declines. This is not acute decline, but progresse, over years or decades, producing the gradual endocrine insufficiency that the original article documented in its cohort and that the longitudinal case study has observed over thirty years (Craddock, Redacted Science).
The distinction between pathological pituitary failure and programmatic pituitary exhaustion is clinically significant. Standard endocrinology treats pituitary insufficiency as a glandular disease — a failure of the organ itself. The framework described here treats it as the predictable outcome of a preserved system running without the environmental context that would allow its program to complete. The treatment implications are fundamentally different: the gland does not need to be replaced or supplemented. The program needs to be understood, and ideally, completed or safely resolved.
8.5 Consequences
The trinity's collapse was not a single event. It was a geographic gradient that followed the dispersal.
In the Rift Valley core zone, where all three keys remained present, the full program continued to operate. The social structure sustained it. The elders produced transmissible knowledge. The phenotype persisted. But at the edges of the expanding human range and in environments without saline-oscillating water sources, the third key was missing. Infants born in these peripheral populations carried the symbiont (key one) and may have achieved adequate colonization density (key two), but without the electrolyte oscillation, the preservation program did not fully activate. The developmental transition completed. Pump-dominant adults emerged.
These pump-dominant individuals carried a compound advantage in the new environments. They were physically strong through their reproductive years without the transitional decline phases that the deepened program now produced in preserved individuals. They were free from the social dependency the trinity required. They did not need a group to feed and protect them through vulnerable phases, and they were in environments where the elder's specialized knowledge, refined for Rift Valley conditions, was less immediately applicable. The survival value of the preserved elder's cognitive output diminished in proportion to the distance from the ecological context that output was calibrated to.
Pump-dominant individuals outcompeted preserved individuals reproductively at the geographic margins. The elder-protecting social structure, without elders to protect, lost its adaptive function. The trinity collapsed then collapsed. Deteriorating not from the center, but from the edges inward. As the pump-dominant phenotype expanded through the peripheral populations and eventually back into contact with the core zone, the reproductive advantage compounded. The social structures that had sustained the program for millions of years were undermined by a simpler, more reproductively efficient phenotype that did not require them.
The symbiont persisted commensally. It persists today in virtually every human. The program persists in the organism's chromatin-encoded memory (Section 5.8). But the hardware the program requires, notably the preserved suction heart, the maintained pituitary, is no longer produced because the environmental key that activated the preservation sequence no longer turns in any modern lock. A deep system state that the organism still remembers how to enter, in a host whose developmental program no longer permits the entry.
The modern condition described in Craddock Case Studies, a full activation of the ancient program triggered by iatrogenic circumstances in an adult whose developmental transition completed normally decades earlier, represents the most extreme edge case: the old program running on hardware that was never preserved for it. That it has been sustained for over thirty years under these conditions speaks to the robustness of the program itself and raises the question addressed in Section 9.2: what could be achieved with the full playbook and a medical system prepared to support the process?
8.6 Salt Sensitivity and the Vestigial Conversion Mechanism
The Saline Oscillation Hypothesis predicts that the cardiovascular response to sodium variation should differ across individuals in proportion to the signaling density of the distributed commensal system described in Section 5.7. Modern clinical data on salt-sensitive versus salt-resistant hypertension is consistent with this prediction.
Approximately one-third of the adult population globally exhibits hypertension, and salt sensitivity, the degree to which blood pressure responds to changes in dietary sodium. varies substantially across individuals. Genetic variation, renal sodium handling differences, RAAS polymorphisms, and vascular reactivity have each been proposed as contributing factors. No unified mechanistic explanation has been established.
The framework presented in this paper proposes a two-gate model in which salt sensitivity and its clinical consequences are governed by two independent variables: the signaling density of the commensal Candida population (gate one), and the cardiac architectural capacity to complete the conversion sequence (gate two).
Gate One: Signaling Density
Section 5.7 established that C. albicans colonization is near-ubiquitous in humans, with the conventionally cited 40–60% detection rate reflecting assay sensitivity rather than true prevalence. What varies between individuals is not whether the organism is present but the density, distribution, and aggregate signaling output of the distributed system at each tissue interface.
In a host with high commensal density, the organism's aggregate vascular signaling is proportionally greater: more PGE₂ production from host-derived arachidonic acid (Section 5.5d), more farnesol interacting with voltage-gated calcium channels (Section 5.5), more ECS-mediated modulation of cardiac conduction and perfusion dynamics (Section 4.3), and a larger collective footprint across the vascular control systems the organism accesses. When this host encounters a sodium perturbation, whether excess sodium producing volume expansion or sodium deficit triggering SIADH-type water retention, the distributed system's vascular signaling amplifies the cardiovascular response. The response scales with the operator's density, not with a defect in the host's hardware.
In a host with low commensal density, the same sodium perturbation meets insufficient signaling mass to drive a meaningful vascular response. The hardware is identical. The operator is present but below the threshold at which its aggregate output moves the system.
This reframing generates predictions that the hardware-only model does not. Salt sensitivity increases with age (Weinberger and Fineberg, 1991). This is consistent with the documented tendency for Candida colonization density to increase over the lifespan through cumulative antibiotic exposure, hormonal changes, immune senescence, and declining mucosal barrier integrity. A person who is salt-resistant at 25 may become salt-sensitive at 50 not because their cardiovascular genetics changed but because their colonization deepened in the intervening decades. The hardware-only model requires a genetic or structural change to explain this shift.
The colonization model requires only what is already documented: commensal density changes over time.
Geographic and demographic variation in salt sensitivity prevalence is similarly consistent. Populations with different dietary histories, antibiotic exposure patterns, and microbiome compositions carry different colonization profiles. This connects directly to the mycobiome prediction in Section 10.1: comparative Candida colonization profiles in populations near hypersaline versus freshwater sources in the modern East African Rift System should correlate with population-level differences in salt sensitivity, if commensal signaling density is the mediating variable.
Gate Two: Cardiac Architecture
The first gate determines whether the vascular response initiates. The second gate determines whether it resolves.
As described in Section 8.1, every mammal is born with suction-dominant cardiac architecture. In the ancestral Rift Valley context, where all three activation keys were present (Section 8.3), the symbiont preserved the neonatal suction-dominant heart into adulthood through continuous ECS-mediated management of cardiac conduction during the critical postnatal developmental window. These preserved individuals entered the saline oscillation environment with the cardiac architecture the program required.
When they encountered freshened water sources during humid periods, their systems, already calibrated to higher electrolyte concentrations, responded with SIADH-type water retention, volume expansion, and elevated blood pressure (Section 4.1). In an unmanaged host, this would be a crisis event. In a host with a preserved suction heart and a biochemical computer onboard in sufficient density, the elevated blood pressure did not merely provide passive perfusion pressure. It actively amplified the suction mechanism. Increased blood volume and elevated systemic pressure meant more venous return available per cardiac cycle (basic fluid mechanics). In a suction-dominant heart, more input volume produces greater diastolic pull. This is basic conservation of flow in a suction-driven system. The pituitary, sitting in the preferential perfusion zone described in Section 4.3, outside the blood-brain barrier and directly in the suction path, received increased perfusion proportional to the increased flow. The BP spike amplified the suction heart's throughput, which amplified pituitary perfusion, which amplified the symbiont's endocrine governance capacity through the pituitary at exactly the moment the program needed maximum control to drive the conversion. The system used the crisis as the fuel for the solution. What would have been a physiological emergency was instead a conversion, and blood pressure normalized as the circulatory reorganization completed.
The longitudinal case study documents this resolution in a modern subject. During the 2022 IVC constriction release event, the system transitioned through altered vascular dynamics into a reorganized perfusion state, after which approximately 30 pounds of retained fluid was lost over six weeks (Craddock, 2022 log; Craddock, Redacted Science). The waypoint resolved because the conditions for the next step in the sequence were met.
In modern adult populations, the three-key activation conditions described in Section 8.3 are not met during postnatal development. The third key, the electrolyte oscillation signal — is absent. The normal developmental transition from suction-dominant to pump-dominant cardiac architecture completes on schedule. By adulthood, the pump-dominant heart cannot transition back to suction-dominant operation (absent extreme iatrogenic intervention). Gate one opens, and the commensal system's aggregate signaling drives the vascular response to sodium perturbation. Gate two is closed. This is not because of a genetic mutation, but because the developmental window during which the suction heart could have been preserved has long since passed. The elevated blood pressure, designed to be transient in a preserved host, becomes sustained in one whose cardiac architecture matured past the point of return.
The Vestigial Trap
This is the vestigial trap: a mechanism that was adaptive when the full conversion sequence was available becomes pathological when the sequence cannot complete. The waypoint persists for years, then decades. Sustained elevated blood pressure damages the vascular endothelium, promotes cardiac hypertrophy, compromises renal function, and increases stroke risk — consequences of maintaining a transient state indefinitely. The system is not broken. It is executing the first step of a program whose subsequent steps are no longer available.
The oscillation model explains why both excess and deficit sodium exposure produce the same clinical outcome. The ancestral system was designed to cycle: salt buildup during arid periods calibrated the host's electrolyte set point upward; freshwater transition during humid periods created the delta that triggered the vascular response. Both directions are relevant: salt buildup calibrates and then freshwater transition triggers. In modern humans frozen on one side of a cycle that no longer oscillates, deviation in either direction from the system's calibrated set point activates the response. The clinical literature's difficulty in establishing a simple linear relationship between sodium intake and blood pressure may reflect the fact that the underlying mechanism responds to the delta from calibration, not to the absolute sodium level.
Antihypertensive Pharmacology Within This Framework
The standard clinical response to sustained hypertension is pharmacological blood pressure reduction through ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, or diuretics. Each class targets a different component of the vascular response machinery. All succeed in reducing the measured pressure. None addresses the colonization state or the conversion attempt that produces it.
Within this framework, antihypertensive therapy suppresses the waypoint without resolving the program that generated it. The distributed system's signaling remains intact. The conditions that triggered the response have not changed. The system re-initiates. The pressure returns. Dosage increases. Additional agents are added. Treatment-resistant hypertension, often requiring three or more agents at optimal doses, is consistent with a system that keeps restarting a program rather than a static defect being incompletely treated.
This interpretation does not argue against antihypertensive treatment. In the absence of the full conversion sequence, sustained elevated blood pressure causes organ damage and death. Pharmacological reduction prevents this damage and is clinically necessary. The framework argues that the condition being treated is a vestigial program, and that the treatment's requirement for lifelong continuation reflects the ongoing nature of the conversion attempt rather than a chronic disease in the conventional sense.
Prevalence as Evidence of Conservation
Essential hypertension affects approximately 1.3 billion people globally. This prevalence is consistent with a conserved mechanism from a period when the hominid population was universally colonized and under oscillatory electrolyte pressure in the East African Rift Valley. If the vascular response were a rare polymorphism, it would not affect a third of the global population. Its near-universal prevalence suggests it was the ancestral default and the standard response of a colonized mammalian host to the environmental conditions under which the coevolutionary program operated. The variation in salt sensitivity across the modern population maps onto the variation in colonization density documented in the mycobiome literature, rather than onto a binary genetic division between responders and non-responders.
Limitations and Pharmacological Confounds
This subsection is the most theoretical component of the cardiac architecture hypothesis, which is itself identified as the weakest link in the current framework (Section 10.4).
A natural question is whether existing antifungal pharmacology provides a test: if colonization density drives salt sensitivity, does reducing colonization reduce blood pressure? Current evidence does not cleanly address this question due to pharmacological confounds inherent in available antifungal agents. Azole antifungals, particularly itraconazole and posaconazole, inhibit mammalian CYP enzymes involved in steroid metabolism, producing mineralocorticoid excess and sodium retention independent of any effect on the commensal population via a direct drug-on-host-steroidogenesis artifact that confounds interpretation. Amphotericin B, a fungicidal polyene that lyses fungal cells through ergosterol binding, produces acute hemodynamic instability consistent with the rapid release of intracellular contents from a dying population, as C. albicans maintains intracellular potassium at 200–300 mmol/L (Section 5.5e), and mass lysis would produce an acute electrolyte dump sufficient to perturb host hemodynamics. Fluconazole, which is fungistatic rather than fungicidal at standard doses, does not produce a strong blood pressure signal, consistent with gradual colonization reduction without mass die-off allowing host compensatory mechanisms to absorb the change. None of these observations cleanly tests the colonization-density model because none isolates the variable of interest, commensal signaling density, from the drug's independent effects on host physiology.
A clean test of the two-gate model would require mycobiome-stratified blood pressure studies: quantitative Candida colonization assessment combined with standardized salt sensitivity testing in the same cohort, with multivariate adjustment for age, BMI, renal function, and RAAS genotype. A correlation between colonization density and salt sensitivity, independent of the standard clinical predictors, would support gate one. Separately, comparative assessment of diastolic suction contribution in salt-sensitive versus salt-resistant individuals, if technically feasible, would address gate two. These studies have not been conducted.
VIII.VII Gate One in Depth: The Barrier Cascade and the Priming Phase
Section 8.6 introduced Gate One as signaling density, ie. the aggregate output of the distributed commensal system at each tissue interface. This framing is sufficient to explain the salt sensitivity gradient across the general population. It is not sufficient to describe what happens when Gate One actually opens in a specific host at a specific moment. The mechanism of the opening event has architectural implications the two-gate model as originally stated does not fully draw out.
The longitudinal case study (Craddock, Redacted Science; Craddock, 2022 log; Craddock, Terminal Onset DI) documents the opening of Gate One as a specific physical event on a specific date in 1995, following weeks of preparatory pathology. Reading the event mechanistically clarifies three things: what physically constitutes the opening; why the opening is not a single moment but a two-phase process; and what makes the barrier breach-permissive in some hosts and not others despite the triggering behavior being common.
The Barrier Cascade Framing
The framework’s precision-mapping method can be stated compactly: the path of the condition is the sequence of physical barriers that fall, each falling because the prior barrier’s failure has created the conditions the next barrier cannot withstand [a biological Rube-Goldberg machine]. Once Gate Two remains closed (adult pump-dominant heart in place) and Gate One has opened, the sequence of subsequent barriers proceeds along a determined path — not because the physics alone forces linearity, but because the coevolved organism’s configured response aligns with each successive mechanical state as it arrives. The path is deterministic at the intersection of two variables: the passive physical consequence of the prior barrier’s fall, and the organism’s configuration-gated response to the resulting state. Where these align, the next barrier falls. The alignment is not accidental. It is the product of the coevolutionary architecture Paper A and Sections 4–5 of this paper describe. [Understand, this is Programmed Failure; however, due to version conflict - we have a different cardiac system - the end result for humans of today is various stuck-state chronic conditions created by gates that never open as demonstrated in other Redacted Science Initiative Papers]
Gate One as a Two-Phase Event
The 1995 opening in the case study did not occur in an unprepared host. Weeks of renal pain on drinking, chronic fluid overload driven by prior undiagnosed SIADH episodes (one severe enough to require dialysis in the college years), and the specific pharmacological cascade documented in the TODIC record all preceded the acute bearing-down event on the evening the transition occurred. This priming is not incidental to the mechanism. It is the mechanism’s slow first half.
Gate 1a — Priming Phase. Progressive compromise of renal parenchymal and urothelial paracellular integrity, developing over weeks to months. The clinical signal is capsular pain on drinking, produced by acute renal volume expansion into interstitium that a compromised barrier is no longer clearing; the SIADH pattern is the pituitary’s early recruitment into functions its normal governance scope does not include. During Gate 1a, the barrier’s tight junction proteins are being remodeled by the same organism-mediated processes documented at other mucosal surfaces: candidalysin-driven ATP efflux, claudin isoform shifts, and localized inflammation altering paracellular selectivity. The barrier is not yet breached, but its breach threshold is falling.
Gate 1b — Breach Event. Acute pressure applied to the primed barrier — in the case study, sustained bearing-down against inability to urinate — produces paracellular flux of the dominant extracellular solute across the compromised junctions. That solute is NaCl, not because it is the smallest ion by radius (it is not) but because paracellular tight junctions in mammalian epithelia are cation-selective for Na+ via claudin isoform expression, because Na+ is the dominant ECF cation at approximately thirty-five times the K+ concentration, and because K+ is intracellularly compartmentalized by active Na/K-ATPase transport rather than freely available for bulk flow. Under sustained pressure against a compromised biological barrier, NaCl and water are what breach first. This is the first physical barrier of the cascade. [Takes me back to undergrad labs]
The Balancing Response
Persistent Na+ loss through the breached barrier destabilizes the Na/K-ATPase gradient. Pump efficiency depends on the sodium gradient it is asked to maintain; a leaking barrier that keeps Na+ from being sustained at physiological ECF concentration reduces the pump’s capacity to clear K+ from the ECF into cells. K+ accumulates in the interstitial compartments slowly over the timescale of the Na+ leak — years to more than a decade in the case study, with the accumulation reaching the cardiac tolerance threshold thirteen years after Gate 1b fired.
Because adrenal capacity is being progressively compromised in parallel (Stage 1 of the case study: one adrenal begins gradual failure at the same event), aldosterone-mediated Na+ retention cannot succeed against the breached barrier. The compensatory function is picked up by the pituitary, initially through ADH-mediated water retention (Route 2 governance, per Paper A) sustaining volume despite the ionic drift, and secondarily through Route 1 modulation of the remaining adrenal’s output. This is the pituitary functioning outside its baseline scope — controlling Na/K balance dynamics that in an unbreached host are handled entirely downstream. The organism, positioned to sense and modulate at each of these compartments, is co-located and configuration-locked to the progression, waiting for the interstitial K+ load to reach the threshold that permits the next barrier to fall.
The Co-Authorship Question
If Gate 1a is barrier remodeling that occurs over weeks to months before any acute trigger, the question of what makes the barrier breach-permissive in some hosts and not others resolves toward the commensal signaling density variable that Section 8.6 already established as Gate One’s population-level determinant. High-density signaling produces the tight junction remodeling that lowers the breach threshold; low-density signaling does not. Bearing-down against impaired output is a common human behavior; breaching under it is not. The differentiating variable is the priming state of the barrier at the moment of pressure application, and the priming state is set by the aggregate commensal signaling the host carries.
This makes Gate One’s opening co-authored rather than merely triggered. The organism does not merely wait for Gate 1b; it is the reason Gate 1a develops at all. The framework should state this directly, both because it clarifies why the two-gate model produces the population-level salt sensitivity distribution observed clinically, and because it identifies Gate 1a as the phase during which intervention remains possible before the architectural transition of Gate 1b makes the subsequent path linear.
Testable Predictions
1. Idiopathic SIADH epidemiology. The case study documents a sub-threshold SIADH episode in the college years that resolved without a bearing-down trigger presenting; the 1995 episode fired Gate 1b because the trigger did present. If Gate 1a can manifest as SIADH without proceeding to Gate 1b when no acute trigger occurs, then idiopathic SIADH in the general population should be substantially more prevalent than diagnosed cases suggest, with a subset progressing to the barrier-cascade pattern the framework describes when triggering events occur. Long-term follow-up of idiopathic SIADH cohorts, stratified by subsequent exposure to conditions producing sustained abdominal or urinary tract pressure, should reveal this progression pattern.
2. Pain on drinking as an early Gate 1a marker. Renal capsular pain elicited specifically by water intake, in the absence of infection, obstruction, or structural pathology on standard imaging, should correlate with elevated commensal Candida signaling markers and precede any measurable electrolyte disturbance by weeks to months. This is a testable clinical marker for pre-breach Gate 1a status.
3. Reversibility during Gate 1a. Because Gate 1a is a slow remodeling phase, it should remain susceptible to intervention that would be futile once Gate 1b has fired. Reduction of commensal signaling density via targeted antifungal exposure, epithelial repair support, and correction of the underlying fluid overload during the Gate 1a window should all reduce breach probability. This predicts a specific therapeutic window that current SIADH management does not exploit. [I think this was even discussed in the Article]
4. Microadenoma prevalence tracking Gate 1a duration. If pituitary recruitment into Na/K balance functions begins during Gate 1a, and if Paper A’s characterization of the microadenoma as a tissue stress response to sustained abnormal demand is correct (Section 4.7 of Paper A), then microadenoma prevalence should correlate with the duration of the Gate 1a phase. Hosts in whom Gate 1a persists sub-threshold for years without breaching should nonetheless show elevated microadenoma detection rates on dedicated pituitary imaging relative to the general population.
Closing Structural Point
The path to precision-mapping this condition is the identification of what barrier must fall next along a logical path. Each barrier defines the conditions of the next. The organism is present at each and is configuration-locked to the sequence. Where the ancestral program had all subsequent gates open by developmental preservation, the modern host arriving at Gate 1b through the priming-and-breach mechanism described here traverses each subsequent gate under whatever architectural cost is available to pay it. The linearity, once the sequence starts, is not the framework’s invention. It is the coevolutionary architecture executing its ancient program in a host whose preservation windows have all closed. What the framework provides is the map.
________________________________________
9. Homo Candidus: The Suppressed Phenotype
9.1 Definition
We designate Homo candidus as the symbiont-active hominid phenotype: a functionally distinct physiological and cognitive state produced by full activation of the ECS-mediated coevolutionary program described in this paper. Homo candidus is not a separate species but a conditional phenotype, the same organism operating under different management. The differences are material: altered cognition, altered pain processing, altered metabolic strategy, altered circadian architecture, altered perfusion dynamics, and throughout (but even more so in the late stages) enhanced creative and analytical output documented in both the historical cohort and the longitudinal case study (Craddock, Redacted Science).
If the trinity model is correct, this phenotype was the engine of early human cognitive and cultural advancement. The lucid elders of Homo candidus, sustained by social protection and pharmacological support, produced the transmissible knowledge that accumulated into what we now call civilization.
More broadly, given the evidence presented in the Craddock Case Studies, this is not a disease invention of modern medicine but a deep system state that the organism still remembers how to enter.
9.2 The Attention “Gap” Issue
Despite the apparent potential lethality of fungal pathogens and the number of deaths they cause, Fungal research has been neglected. Figure 3 illustrates the gap in funding compared to the attributable deaths. Approximately 2% of total infectious disease funding went towards a category with approximately 15% of the attributed deaths.
Figure 3 Infection Disease: Estimated Annual Deaths vs. Research Funding
Type	Estimated annual deaths	Comparative annual research funding	Sources
Fungal	~1.5M – 3.8M deaths/year	~$100M–$500M (very rough, fragmented, underfunded)	Mortality: 
Funding context: neglected disease funding ~$4.17B total but overwhelmingly not fungal 
Bacterial	~7.7M deaths/year	~$1B–$3B+ (AMR + bacterial infection R&D)	Mortality: 
AMR burden + funding priority context: 
Viral	~2–4M/year baseline (non-pandemic) 
(can exceed 8M in pandemics)	~$3B–$10B+ (highly variable; COVID spike drove peaks)	Mortality (aggregate baseline + pandemic variability): 
Funding totals global health R&D ~$8.7B with heavy viral allocation (HIV, COVID): 

Fungi were first noted to cause disease in 1835. The germ theory of Pasteur and Koch dominated the second half of that century. Fungi were not the priority. By the early 20th century, histoplasmosis, coccidioidomycosis, and blastomycosis were identified. This is when medicine first gave note that fungi can infect internal organs. By the mid-20th century, suddenly candidiasis and aspergillosis become a major cause of death – subsequent to the introduction of antibiotics in scale. These organisms were here, but they were not causing deaths until after antibiotics were developed - drugs designed to target the ecology of the internal biome. Clearly, while not the sole factor, widespread antibiotic use contributed to increased fungal disease. Yet, it remained deprioritized in funding.
In 2022, the World Health Organization issued their very first list of fungal priority pathogens. Notably, c. albicans is listed in the Critical Priority Grouping – last but it is in there. They note, “Tackling the problems posed by IFD will require increased research funding, targeted at the key priorities, new antifungal medicines and improved diagnostics.” This is the hunt and kill approach. Commensal didn’t mean you shouldn’t nuke it. It’s just a bug. Squish it.
Except it isn’t just a bug, is it? The C. albicans toolkit is rich. This author can explain it to you as no one else can, if there is a knob, C. albicans can turn it.
But, in 1964, the worlds leading mcyologists got together and agreed – C. albicans was an opportunistic pathogen, nothing more. It had a high fatality, and “could diagnose better than a clinician.” Yes, that line is literally from the handbook for the First Symposium on it in 1964. Everyone was told to kill it. No need to look further, this is pure pathogenicity. Of course, it’s in everyone and NOT killing them – but if it shows up on a test, that means kill it. The logic is astounding. Bees sting. If we kill all the bees, where are we?
The attention “gap” exists at all levels from institutional concern, to bench funding, to journal scope, medical education, and clinical encounter. The knowledge gap is even wider. My clinician at the Cleveland Clinic said he tells his residents they “get more stupid each year, but that’s ok.” The knowledge is siloed by the current system, almost by design.
I had the same PCP for 30 years. I told him the exact name of my condition and tried to describe it for decades. Over the decades, I went to just about every specialty multiple times except endocrinology. Why skip that one, you ask? I didn't skip it. I requested it for years, decades. I got one appointment with a diabetic endocrinologist. That's what specialization does. Over the last 4 years, I tried again (unsuccessfully) to get an endocrinology referral, despite my symptoms. They were “clearly not endocrine-related.” My tests were fine, after all. CMP, CBC, thyroid, all checked out. My Autoimmune panel? Peachy. Normal range.
C. albicans is a pathogen that operates in everyone’s territory but is never looked at in a systems thinker’s approach. There isn’t a box in anyone’s system that says “ecological imbalance causing symbiotic dissonance.” Here is a test: Go to your clinician and ask him if he knows that the Na/K pump is? Hopefully, they get that part right. Then ask them how it works. If they make it past that, ask them if it can go in reverse. My personal experience walking in with items 1, and 2, given that starting point, they will still always get 3 incorrect and look at you like you are nuts.
They can remove the archaic clinical literature term “hypophyseal failure” implicating it as “hypopituitarism.” Those really don’t mean the same thing. The organism keeps on computing either way.
9.3 Ethical Implications of the Redaction
The suppression of the original research documenting this coevolutionary architecture, specifically the “redaction” described in (Craddock, Exposé), raises ethical questions that extend far beyond a single retracted article.
The redaction suppressed not merely a clinical observation but the existence of a functionally distinct human phenotype. If Homo candidus is real, then every person currently living with undiagnosed symbiont activation is being treated for a pathology that is actually an architecture. They are being medicated out of a phenotype that, in the appropriate social context, would be producing the most valuable cognitive output in their community. This is not a missed diagnosis; it is an active harm.
The understanding that the ECS serves as an inter-kingdom communication interface has implications extending across medicine: diabetes management (the historical cohort maintained normal blood glucose despite blocked insulin pathways), renal medicine (the host compensated for kidney damage through alternative filtration routes for over 30 years), and the broad category of conditions currently classified as idiopathic, including those attributed to ECS dysregulation or other directly related systems, more specifically the endocrine system in all its axes, the gut-brain axis, and immune modulation. The ECS does not operate in isolation; it interfaces with every major regulatory system in the body. Disruption of the ECS-mediated symbioticarchitecture could manifest as autoimmune dysregulation, endocrine imbalance, gastrointestinal dysfunction, or neurological disorder, depending on which aspect of the interface is most affected.
The ethical argument against suppression is straightforward: the potential medical value of understanding this architecture vastly outweighs the ethical discomfort associated with the knowledge that human physiology can be deliberately altered through symbiont activation. Science has historically managed dangerous knowledge through regulation, not erasure. The decision to redact the original research was a decision to erase knowledge of a human variant from the scientific record.
The implications are stark, if a person can achieve a normal existence with a 30+ year survival despite fundamentally altered physiology with no substantial medical intervention, while having normal lab and imaging test results for almost that entire period and having only the basic idea (and completely unsupported by any externality) of the changes taking place, a question must be asked – how long can this state be maintained?
“So yeah, I’m alive because I got lucky with a few insights. But what if someone had all the knowledge? What if someone walked into this with a blueprint? How long could they live then? Could they manage this for more than the three decades I did? A normal lifespan, maybe? That would be almost evolutionary”. (Craddock, Redacted Science)
10. Discussion
10.1 Testable Predictions
The Saline Oscillation Hypothesis generates several testable predictions:
1. Paleochemical analysis of hominid dental enamel and bone from the Turkana Basin should show fluctuating electrolyte and mineral signatures corresponding to known lake salinity cycles.
2. Comparative cardiac anatomy across primates and across postnatal developmental stages should reveal variation in the relative contribution of diastolic suction vs. systolic ejection. The developmental preservation model (Section 8.2) predicts that the suction-to-pump transition is a normal postnatal maturation process; comparative echocardiographic data from neonatal through adult stages across primate species would establish the baseline developmental trajectory against which symbiont-mediated preservation could be assessed.
3. Mycobiome analysis of populations living near hypersaline lakes in the modern EARS may show distinct Candida strain distributions or ECS tone profiles compared to populations near freshwater sources.
4. Archaeological evidence of salt-seeking behavior, salt processing, or salt storage at hominid sites in the EARS would support the electrolyte-dependence component.
5. Phytocannabinoid residue analysis at early agricultural sites should be examined for evidence that psychoactive plant cultivation preceded or paralleled caloric crop cultivation.
6. Distance running performance in Rift Valley populations (particularly the Kalenjin of Kenya) may reflect an ECS architecture refined by the coevolutionary program; comparative ECS tone profiles between elite East African distance runners and matched non-Rift Valley controls would be informative.
7. Molecular dating of the C. albicans / C. dubliniensis divergence, if resolved to the Plio-Pleistocene window (~2–5 Ma), would provide strong independent support for the hypothesis; the directional selection observed in C. albicans (virulence gene family expansion) versus C. dubliniensis (reductive evolution) is predicted by the framework.
8. Epigenetic analysis of populations in the modern EARS, examining methylation patterns in genes governing electrolyte handling, vascular tone, and ECS regulation, compared with non-Rift Valley populations, could reveal persistent signatures of the coevolutionary program.
9. Phenobarbital-induced symbiont activation. Exposure of commensal-state C. albicans populations to phenobarbital in a simulated gastric environment containing both glucose and a gastric mucosal tissue analog (mucin-coated epithelial cell culture or equivalent substrate) under acidic conditions should produce a measurable shift from yeast-form glucose metabolism to hyphal-form tissue invasion, including upregulation of secreted aspartyl proteases (SAPs), phospholipase activity, and CYP450 enzyme induction. This experiment would test the iatrogenic symbiont activation mechanism proposed in Section 5.1 and is consistent with both the longitudinal case study documentation (Craddock, 2013; Craddock, Redacted Science) and published case reports of phenobarbital-associated mucosal ulceration at variable anatomical locations.
10. Evo 2 computational genomics. Functional analysis of the approximately 1,300 C. albicans genes with no orthologs in other yeast species, using genomic foundation models such as Evo 2 (Arc Institute, 2025) trained across all domains of life, should reveal functional signatures consistent with host-interaction roles, including predicted GPCR ligand production, immune modulation, cross-kingdom signaling capabilities, peptide-processing enzyme homologs, peptide transporter regulatory elements, and neuropeptide-mimicking sequences that traditional comparative genomics within the fungal kingdom has not resolved. The C. albicans genome (approximately 14.3 Mb across 8 chromosomes) exceeds current single-pass context windows but is accessible chromosome by chromosome, with the smallest chromosomes falling within the 1 million token limit of current models. A specific analytical pipeline is proposed: (1) variant effect scoring across all uncharacterized genes to identify positions under functional constraint, (2) extraction and clustered not only against known host-interaction gene families from obligate symbionts but also against mammalian prohormone convertase substrates and neuropeptide precursor architectures, (3) sparse autoencoder feature detection to flag genes with signatures consistent with GPCR ligand production, immune modulation, or quorum sensing, and (4) gene sequence completion to identify genes whose architecture diverges from patterns learned across the training set of 128,000 organisms, suggesting novel functional roles. As context windows expand in successor models, whole-genome single-pass analysis will become feasible.
11. Cholinergic interface characterization. The confirmed presence of a functional muscarinic receptor in C. albicans (Nile et al., 2018) and the documented elevation of host acetylcholine levels during Candida infection suggest that the cholinergic system represents an active bidirectional signaling interface between symbiont and host.  Comparative analysis of choline metabolism, acetylcholinesterase activity, and vagal tone in Candida-colonized versus germ-free animal models would establish whether this interface contributes to the symbiont’s regulatory influence on host autonomic function.
12. Extracellular vesicle-mediated cross-kingdom RNA transfer. Purified EVs from C. albicans hyphae should be incubated with human epithelial cells and macrophages, followed by small RNA sequencing of the recipient cells to identify fungal-origin sRNAs that have been internalized. Predicted fungal sRNAs should be cross-referenced against the human transcriptome for potential gene-silencing targets using standard sRNA target prediction algorithms. The prediction from the coevolutionary framework: at least a subset of fungal sRNAs delivered via EVs will have sequence complementarity to human immune or metabolic genes, and incubation of host cells with fungal EVs will produce measurable downregulation of predicted target transcripts in a manner attenuated by host AGO knockdown or by treatment with EVs from an ESCRT-deficient C. albicans mutant producing fewer vesicles. Additionally, comparison of codon usage in C. albicans EV-associated mRNAs against the host codon optimality landscape should reveal whether exported transcripts are more human-optimized than the bulk C. albicans transcriptome, consistent with coevolutionary selection for evasion of DHX29-mediated translational surveillance (Hia et al., 2026).
13. Arachidonic acid competition between prostaglandin and endocannabinoid synthesis: In colonized mucosal tissue models or ex vivo gut tissue segments harboring C. albicans biofilm, levels of PGE₂ and endocannabinoids (AEA, 2-AG) should differ from uncolonized controls in a direction consistent with altered arachidonic acid flux. Specifically, colonized tissue is predicted to show elevated PGE₂ and reduced AEA and/or 2-AG, with the magnitude of change scaling with fungal burden. This effect should be attenuated in ole2/ole2 or fet3/fet3 strains with reduced prostaglandin biosynthetic capacity. Such findings would support the hypothesis that fungal prostaglandin production measurably shifts host lipid signaling balance and may alter host ECS tone through competition within the shared arachidonic acid precursor pool.
14. Non-candidalysin Ece1 peptide functional characterization. The 2024 interactome screen (Lin et al., 2024) identified host protein targets for all eight Ece1 peptides but focused mechanistic investigation on candidalysin alone. Functional characterization of Ece1-I, -II, and -IV through -VIII in both epithelial and immune cell models, using purified synthetic peptides at concentrations achievable in the invasion pocket microenvironment, should reveal whether these peptides constitute a coordinated immune modulation panel. The prediction from the coevolutionary framework: at least two non-candidalysin Ece1 peptides will demonstrate dose-dependent immune suppression through distinct receptor pathways, consistent with a multi-peptide effector strategy rather than a single-toxin virulence mechanism. The LILR-family interactions identified for Ece1-II and Ece1-V (Lin et al., 2024) are the most promising initial targets. If confirmed, this would establish that C. albicans secretes a coordinated peptide effector panel from a single gene product, processed through Kex2p/Kex1p in the same enzymatic logic as mammalian prohormone processing.
15. Peptide transporter function in host-signal sensing. The ten peptide transporters (2 PTR, 8 OPT) of C. albicans are maintained despite having no fitness requirement for gastrointestinal colonization (Dunkel et al., 2013). To test whether these transporters function as environmental sensors in addition to nutrient importers, C. albicans populations should be exposed to physiologically relevant concentrations of gut-derived peptide hormones (GLP-1, CCK, PYY) and antimicrobial neuropeptides (Substance P, NPY) in defined media, and transcriptomic and morphological responses measured. The prediction: exposure to at least one host-derived signaling peptide will produce a measurable transcriptional or morphological response in wild-type C. albicans that is attenuated or absent in the peptide transporter-deficient septuple mutant (opt1Δ opt2Δ opt3Δ opt4Δ opt5Δ ptr2Δ ptr22Δ), indicating that import of the host peptide is required for the response. 16. Colonization-density correlation with salt sensitivity. Quantitative Candida colonization assessment (mycobiome profiling) combined with standardized salt sensitivity testing (sodium loading and depletion protocols) in the same cohort, with multivariate adjustment for age, BMI, renal function, and RAAS genotype, should reveal a correlation between commensal colonization density and salt sensitivity independent of the standard clinical predictors. If confirmed, this would support the first gate of the two-gate model proposed in Section 8.6 and establish commensal signaling density as a previously unrecognized variable in hypertension pathophysiology."
10.2 Relationship to Existing Hypotheses
The Saline Oscillation Hypothesis is compatible with and extends the pulsed climate variability hypothesis (Maslin et al., 2014; Maslin and Trauth, 2009). Where the existing hypothesis identifies environmental instability as the driver of hominid evolution without specifying the mechanism, the Saline Oscillation Hypothesis proposes a specific biochemical pathway (the ECS-mediated fungal-host interaction, activated by SIADH-type electrolyte disruption during freshwater transitions after saline acclimation) as the mediating mechanism between environmental change and evolutionary outcome.
It is also compatible with the variability selection hypothesis (Potts, 1998), which proposes that hominids were selected for adaptability itself. The ECS is fundamentally a homeostatic regulatory system; its refinement through coevolutionary interaction with a symbiont that requires metabolic flexibility would directly select for the kind of adaptive plasticity Potts describes.
10.3 Coevolutionary Precedent for Signaling Complexity
The multi-receptor, multi-molecular-class signaling architecture described in Section 5 invites an obvious objection: the system is too complex to have emerged through pairwise coevolution between a single fungal species and its mammalian hosts. A decade of experimental work from the Meyer laboratory provides a direct empirical answer across three complementary studies.
Borin et al. (2023) demonstrated that Escherichia coli and bacteriophage Φ21, starting from isogenic populations in well-mixed cultures, diversified into elaborate nested-modular cross-infection networks in just 21 days, showing that "multiscale network structure can evolve rapidly under simple ecological conditions without spatial structure [...] illustrating Darwin's idea that simple adaptive processes can generate entangled banks of ecological interactions." Zaman et al. (2014), using a digital evolution platform, showed that "coevolution of hosts and parasites greatly increases organismal complexity relative to that otherwise achieved," and that coevolved hosts evolved genomes that were "also more phenotypically evolvable," supporting "a general model whereby antagonistic interactions and natural selection together favor both increased complexity and evolvability." Gupta et al. (2022) then measured the fitness landscape of bacteriophage λ as it coevolved with E. coli using high-throughput gene editing-phenotyping technology, providing "direct evidence for the role of coevolution in driving evolutionary novelty" and demonstrating that the fitness landscape is not static but a shifting seascape whose contours are continuously reshaped by the coevolutionary process itself, opening adaptive pathways inaccessible to either partner evolving alone.
The implications for the framework presented here are direct. The Plio-Pleistocene salinity oscillations described in Sections 6 and 7 imposed thousands of environmental reversals on the Candida-hominid partnership, each cycle constituting a serial-passage event under reciprocal selection. If 21 days of phage-bacteria coevolution in a flask generates multiscale network complexity, and coevolution systematically drives both increased trait complexity and increased evolvability, then 200 million years of fungal-mammalian coevolution under fluctuating environmental pressure is not merely sufficient to produce the signaling architecture documented in Section 5. It would be surprising if it did not. The objection is not that the system is too complex. The objection, in light of the experimental evidence, would be that it is too simple
10.4 Population Structure, Differential Selection, and the Genetic Shadow of Homo candidus
Recent population genetic evidence provides independent support for the coevolutionary framework presented in this paper. Rogers et al. (2026) applied site pattern frequencies and bootstrap model averaging to archaic and modern human genomes and identified a two-superarchaic model of Pleistocene population structure, with 98% bootstrap model weight over the single-superarchaic alternative. Their analysis estimates that a previously uncharacterized African population, designated "Z," diverged from the lineage leading to modern humans at approximately 1.3 Ma (95% CI: 1.181–1.428 Ma) and subsequently contributed 19.6% of early modern human ancestry (95% CI: 12.4–26.4%) through admixture prior to the out-of-Africa dispersal.
The authors explicitly identify the central puzzle their model raises: how two African hominin populations remained reproductively isolated for roughly a million years in the absence of continental-scale geographic barriers. They note that Africa's deserts were not continuously arid and that no physical boundary comparable to a mountain range or ocean channel has been identified. The isolation mechanism remains unresolved within their framework.
The Saline Oscillation Hypothesis offers a candidate mechanism. The amplifier lakes of the Eastern Rift, described in Section 2.2, function as periodic barriers to migration. During wet phases, when precessional forcing fills rift basins to depths exceeding 150 meters and widths spanning the valley floor (Kingston et al., 2007; Trauth et al., 2010), these lakes block east-west movement of terrestrial populations. During dry phases, when the lakes contract or disappear, the barrier drops and populations on either side can mix. The oscillation cycle that deepened the coevolutionary program simultaneously created and removed the geographic barrier that isolated the population undergoing it.
Under this model, Population Z corresponds to the oscillation-exposed lineage. For approximately 1.4 million years (from the onset of intense variability at ~2.7 Ma through the estimated divergence point at ~1.3 Ma), this population experienced recurrent saline-to-freshwater transitions that progressively deepened symbiont integration through the mechanism described in Section 4. The population on the opposite side of the rift barrier, ancestral to the modern-archaic lineage, carried the same commensal symbiont but was never exposed to the electrolyte oscillation that activated the full program. Both populations possessed the same biological components: C. albicans as commensal, a functional endocannabinoid system, and mammalian cardiac architecture. The environmental key turned in only one lock.
The chronology estimated by Rogers et al. is consistent with the Homo candidus framework at every constrained node. Z diverges from the modern-archaic trunk at ~1.3 Ma, within the window of sustained oscillation pressure that began at 2.7 Ma and continued through variability packets at 1.9–1.7 Ma and 1.1–0.9 Ma. The admixture from Z into XY occurs after the Neanderthal-Denisovan split (~500–700 ka) and well before the X-Y separation (~30–50 ka), placing it in the Middle Pleistocene. This implies an isolation period of approximately 600,000–800,000 years between divergence and significant admixture, sufficient for the sustained boundary contact and gradual social convergence described below. The timelines are not contradicted by Rogers et al. at any point. If a population existed in the East African Rift Valley that diverged from the main hominin trunk at ~1.3 Ma, remained isolated for roughly a million years without a geographic barrier, and ultimately contributed nearly 20% of early modern human ancestry, Homo candidus, as described in this paper, is a candidate consistent with every parameter their model estimates.
The result, over a million years of differential selection, would be two populations with divergent phenotypes derived from the same genetic substrate. The oscillation-exposed population developed the Homo candidus phenotype described in Section 8: preserved suction-dominant cardiac architecture, deeper ECS integration, enhanced cognitive capacity, language, and a cooperative social structure organized around collective defense, resource management, knowledge transmission, and the protection of vulnerable individuals during transition phases. The non-exposed population developed along the standard mammalian trajectory: pump-dominant hearts (the normal postnatal developmental outcome in the absence of the preservation program described in Section 8.2), greater structural robustness, but without language, without the cannabinoid flywheel's epigenetic legacy, and without the organizational infrastructure that language and the flywheel produced.
The social asymmetry this creates is the inverse of the physical asymmetry. Population Z, with language, cooperative social structure, and the accumulated knowledge of the flywheel, would have achieved higher population densities and controlled the resource-rich rift corridor and its margins. The non-exposed population, organized in small bands without language-mediated coordination, would have occupied peripheral territory. They were not competitors. They were avoiding Z. For the early portion of the contact period, this was not a contest between equals. It was a dominant, organized population and a fragmented peripheral one.
Gene flow during this early period would have been predominantly outward from Z. Individuals expelled or separated from Z's social structure, hybrid offspring born at boundary contacts, and possibly adopted or captured individuals carried Z's cognitive and ECS-related genetic material into the peripheral population. This genetic leakage was asymmetric: the organizational knowledge and language capacity encoded in Z's genome entered the non-exposed population incrementally, generation by generation, without the full program ever activating in the recipients, because the environmental trigger was absent.
Over hundreds of thousands of years of this boundary contact, the non-exposed population gradually developed social cohesion. Language-associated genes accumulating through admixture provided the substrate. Observational learning at the boundary provided the model. The non-exposed population did not need to independently invent cooperative social structure. They inherited and imitated it from the population that had it. This was a slow process,
but the contact period was long: from the estimated divergence at ~1.3 Ma through the eventual absorption, the two populations coexisted for a span sufficient for incremental social development.
The competitive reversal occurred only after the non-exposed population crossed a threshold of organizational capacity sufficient to challenge Z collectively. At that point, their structural advantage became relevant. Pump-dominant cardiac architecture confers greater tolerance for thoracic trauma: thicker ventricular walls, higher systolic pressure, and no dependence on negative-pressure gradients that a penetrating wound would collapse. In a Pleistocene context with intergroup violence, this is a direct survival differential. A coordinated group of pump-heart individuals, now socially organized enough to act collectively, could sustain combat losses that would be fatal to suction-heart individuals. The advantage was not that the pump-heart population was larger from the outset. It was that once they organized, they were harder to kill.
As the coevolutionary program deepened across oscillation cycles, the transition-phase vulnerabilities described in Section 8 became more pronounced. The Homo candidus phenotype that had been purely advantageous in its early, simpler form now carried periodic costs: physiological transition phases during which individuals required social protection, metabolic demands that constrained dietary flexibility, and the structural vulnerability of the suction heart itself. The social infrastructure that had been Z's greatest advantage became a liability when challenged by an organized opponent who did not share these vulnerabilities.
Hybrid offspring from boundary interbreeding inherited genetic material from both lineages but developed pump-dominant hearts by default, because the environmental trigger required for the preservation program was absent outside the rift corridor. The cognitive advantages downstream of the deepened ECS architecture, encoded in neuroplasticity-related genes, synaptic density regulators, and ECS receptor variants, persisted in the hybrid genome and were subject to positive selection. The cardiac architecture that enabled the full program did not persist, because it was program-dependent rather than purely genetic. The phenotype required the environmental key. Without it, the standard developmental transition from suction to pump proceeded normally (Section 8.2).
Natural selection in the expanding hybrid population favored the pump heart. The suction phenotype could not activate outside the oscillation environment, and on the rare occasions atavistic activation occurred, it carried the transition-phase costs without the environmental context or social infrastructure to support them. Selection did not need to actively eliminate the suction heart. It simply never switched on.
The 19.6% admixture fraction estimated by Rogers et al. represents the genetic shadow of Homo candidus in the modern human genome. It is not expressed as cardiac architecture, which required an environmental trigger that no longer exists. It is expressed as variation in ECS tone, cognitive capacity, salt sensitivity (Section 8.6), and the residual capacity of the program to activate under exceptional circumstances (Section 9). The genes remember. The environment does not. Every modern human carries this fraction. None possesses the environmental key to unlock what it originally encoded.[Kinda proud of this one]
X.IV Pigmentation as a Byproduct of Organism-Driven Pituitary and Epidermal Governance
The conventional explanation attributes the evolution of dark skin pigmentation in the hominin lineage primarily to a single selective pressure: protection against ultraviolet (UV) radiation following the loss of body hair. As hominins moved from forest canopy to open savannah between approximately 2 and 1.2 Ma, reduced fur exposed skin to intense equatorial solar radiation. Melanin serves as a photoprotective shield that prevents UV-induced degradation of folate (vitamin B9), a nutrient essential for neural tube closure and reproductive fitness (Jablonski and Chaplin, 2000). This model is empirically robust and accounts for broad latitudinal clines in skin reflectance. However, it remains incomplete. Extreme pigmentation levels do not map perfectly onto UV intensity alone, and the relatively rapid appearance of deeply pigmented phenotypes coincides with a period of accelerated evolutionary change across multiple systems.
The Saline Oscillation Hypothesis identifies two independent, symbiont-driven mechanisms that would increase melanin production as byproducts of core operations within the Candida albicans biochemical computer. These mechanisms operate additively to UV selection, running in parallel through systemic and local channels consistent with the organism’s documented spatial multiplexing architecture.
Systemic mechanism (pituitary governance). The pituitary perfusion and endocrine governance model (Section 4.3) posits that the fungal symbiont modulates host endocrine output through ECS-mediated signaling and altered cardiac suction/IVC dynamics that preferentially perfuse the pituitary. Pro-opiomelanocortin (POMC), the precursor polypeptide processed in the anterior pituitary, is cleaved into adrenocorticotropic hormone (ACTH), β-endorphin, and α-melanocyte-stimulating hormone (α-MSH). Elevated pituitary activity driven by the symbiont’s perfusion management program during saline-freshwater transitions therefore produces increased α-MSH as an obligate downstream output. α-MSH is the primary hormonal stimulator of melanogenesis. Over millions of years of oscillation cycles, this sustained elevation would ratchet host pigmentation darker as a statistical byproduct of endocrine governance, independent of direct UV pressure. [Brick…]
Local mechanism (epidermal colonization and PGE₂ signaling). Melanocytes in the basal epidermis directly sense Candida albicans via Toll-like receptor 4 (TLR4) and respond by upregulating melanin synthesis as part of an innate immune defense (Tapia et al., 2014). In addition, authentic prostaglandin E₂ (PGE₂) produced by C. albicans from host arachidonic acid via its divergent oxygenase enzymes (Erb-Downward & Noverr, 2007; Section 5.5d) independently stimulates melanocyte activity and melanin production. The organism’s documented capacity for basal epidermal colonization (Schaller et al., 1999; Lopez et al., 2014; Lachat et al., 2022) therefore activates two parallel local pathways—TLR4 recognition and PGE₂-mediated stimulation—driving melanogenesis from within the skin tissue itself. [By brick…]
These symbiont-driven mechanisms align precisely with the critical 2–1.2 Ma window of hair loss, encephalization acceleration, and deepening co-evolutionary integration. During this period the oscillation cycles intensified pituitary governance, expanded epidermal colonization capability, and refined the arachidonic acid economy supporting PGE₂ output. The standard UV-folate model and the fungal biochemical computer model are not alternatives; they reinforce each other. UV radiation supplies the external selective pressure favoring melanin, while the symbiont’s distributed subroutines (systemic α-MSH elevation plus local TLR4/PGE₂ signaling) provide an internal, concurrent driver that pushes pigmentation to extreme levels beyond what UV selection alone would predict.
Geographic distribution and Population Z gene flow. The additive model also accounts for the observed concentration of the darkest native skin reflectance phenotypes in modern African populations. Extreme pigmentation is most pronounced in two regions: the Upper Nile Valley (South Sudan, northern Uganda, southern Ethiopia)—directly downstream of the East African Rift lake systems where saline oscillations operated—and coastal West Africa. Nilotic groups such as the Dinka, Nuer, and Mursi consistently rank among the most deeply pigmented populations measured by reflectance spectrometry. These territories lie immediately adjacent to or downstream of the rift corridor.
The West African hotspot is consistent with gene flow from the oscillation-exposed “Population Z” lineage carrying a deeper symbiont-integration profile (higher colonization density, stronger pituitary governance architecture). Populations receiving greater Z admixture would inherit both elevated α-MSH output and increased epidermal Candida density, amplifying melanin production via the combined systemic and local pathways.
By contrast, the San (KhoeSan) of southern Africa exhibit notably lighter skin despite comparable UV exposure at similar latitudes. They are genetically and geographically distant from both the rift corridor and the West African admixture zone. Under a strict UV-only model this disparity requires additional ad hoc explanations (recent migration, dietary folate compensation). Under the additive coevolutionary model it follows directly: lower admixture from the oscillation-exposed population results in reduced symbiont-driven melanin reinforcement, regardless of UV regime. [By Brick…]
X.IV Testable prediction
Quantitative mycobiome profiling of skin sites, combined with reflectance spectrometry, should reveal a positive correlation between local Candida colonization density and melanin index after statistical control for UV exposure history, latitude, and known pigmentation-associated variants (e.g., SLC24A5, MFSD12, DDB1). Such a residual correlation would demonstrate that the fungal symbiont contributes measurably to human pigmentation through TLR4 and PGE₂ pathways—an independent variable not currently incorporated in standard dermatological or anthropological models of skin color evolution.
This interpretation integrates seamlessly with the broader Mammalia candidus and biochemical computer framework: pigmentation emerges not from a dedicated evolutionary module but as distributed, multi-channel output of the same toolkit already deployed for electrolyte homeostasis, perfusion management, immune calibration, and cross-kingdom signaling. The organism does not “design” darker skin; it simply runs its existing subroutines under the oscillating environmental conditions of the East African Rift, with darker pigmentation arising as a stable, emergent statistical bias.
10.5 21st Century Fungal Biology Emergence
Fungal biology represents a major ecological dimension that was systematically under-recognized within the dominant frameworks of 20th-century biomedical research. During this period, life science priorities were largely organized around host physiology, bacterial pathogenesis, virology, pharmacology, and technological advances in diagnostic and therapeutic instrumentation. Despite contributing substantially to global infectious disease mortality, fungal pathogens historically received on the order of 1-2% of infectious-disease research funding (Head et al., 2014), reflecting a systemic neglect of fungal ecological systems within modern biomedical science. The World Health Organization’s publication of its first fungal priority pathogens list in 2022 (WHO, 2022) represents formal recognition of this longstanding institutional under-prioritization and signals a shift toward consolidation of fungal disease as a central global health concern.
Candida albicans presents a particularly illustrative case of disciplinary fragmentation. Due to its involvement in immunology, microbiology, cell biology, endocrinology, neurobiology, and ecological host–microbe interactions, its functional capabilities have been investigated extensively but often within domain-specific contexts. As a result, key phenomena including cross-kingdom signaling interactions, engagement with the endocannabinoid system, prostaglandin biosynthesis from host-derived substrates, immune polarization dynamics, peptide-processing homologies, extracellular vesicle–mediated communication, bidirectional pH modulation, and ionic competition mechanisms are well documented individually but have rarely been synthesized into a unified ecological framework.
The present work attempts such a synthesis. Rather than introducing novel molecular findings, it integrates established observations across disciplinary boundaries to propose an ecological systems interpretation of C. albicans–host coevolutionary dynamics.
10.6 Limitations
The cardiac architecture hypothesis (Section 8) identifies the weakest link in the current framework. The timing of the suction-to-pump transition is unknown, the threshold at which pump-dominance prevents the symbiont’s program is uncharacterized, and no fossil evidence directly bears on cardiac conduction architecture. This component is currently unfalsifiable and should be treated as a theoretical prediction awaiting methodological development.
The self-citation density, while addressed in the Methodological Note, remains a limitation. The framework depends on observational data from a single longitudinal case study and historical recollections of a redacted source. Independent verification through identification of additional cases, recovery of the original article, or prospective clinical study would substantially strengthen the evidentiary foundation.
The pre-linguistic cannabinoid flywheel (Section 3), while consistent with the known behavioral pharmacology of CB1 agonism and the archaeological evidence for pre-linguistic cooperative behavior, is speculative in its earliest phases. No direct archaeological evidence for hominid phytocannabinoid use before the Neolithic currently exists.
An additional methodological limitation applies to the cross-kingdom signaling evidence presented in Section 5. Virtually all receptor-level interactions between C. albicans metabolites and host signaling systems have been characterized in vitro: isolated compounds tested against isolated targets in controlled media. While these studies confirm that the molecular interactions are possible, they do not demonstrate that they occur in the integrated, spatially heterogeneous, temporally dynamic environment of a living host. The in vitro evidence establishes the components. The assembled system, in which hundreds of metabolites interact with multiple receptor classes simultaneously across variable tissue microenvironments, has never been observed in vivo. The development of metabolomic and receptor-level imaging tools capable of capturing this interaction network in real time within a living host would substantially advance the evidentiary foundation for the framework described here.
11. Conclusion
The Saline Oscillation Hypothesis proposes that the cyclical salinity changes in East African Rift Valley lakes during the Plio-Pleistocene created the environmental conditions (SIADH-type electrolyte disruption during freshwater transitions after saline acclimation) under
which a fungal symbiont capable of managing host perfusion through the ECS gained decisive selective advantage. This activated and progressively deepened an ECS-mediated coevolutionary relationship between Candida species and hominid hosts, producing a functionally distinct phenotype we designate Homo candidus.
The relationship was preceded and supported by a pre-linguistic social flywheel driven by communal phytocannabinoid use, which established cooperative social structure before language emerged. The full trinity (the fungal symbiont, host physiology including cardiac suction, IVC dynamics, and renal pressure management, and cooperative social structure supported by exogenous phytocannabinoid cultivation) was accelerated by the emergence of language and plausibly operational by approximately 1.55 Ma.
The subsequent evolution of pump-dominant cardiac architecture broke this trinity, leaving the symbiont commensal but unable to execute its full program in modern humans. The evolutionary divergence of C. albicans from C. dubliniensis, with directional selection for host-integration genes in the former and reductive evolution in the latter, provides independent biological evidence consistent with the proposed coevolutionary mechanism. The cross-kingdom signaling evidence assembled in Section 5 demonstrates that the organism’s capabilities extend far beyond the endocannabinoid system: confirmed interactions with nuclear transcription factors, ion channels, neurotransmitter receptors, cholinergic signaling, immune cell differentiation pathways, and the incretin system establish a control surface whose breadth is consistent with 200 million years of coevolutionary refinement. The ECS was the original interface. The broader receptor landscape was the expanded toolkit. The organism did not need to evolve new capabilities to respond to saline oscillation. It needed only to deepen the application of capabilities it already possessed, running whatever next subroutine showed the most success. That is evolution. The environmental, paleontological, mycological, and biochemical evidence converge on a single geographic region, the Cradle of Mankind, during the precise temporal window in which these evolutionary changes occurred.

The redaction of the original research that first documented this architecture, treatment, and medical condition represents suppression. This suppression is not just a clinical curiosity, but knowledge concerning a human phenotype that may have been foundational to the development of civilization itself. Even without those implications, the loss to science has caused a multi-generation loss of scientific exploration into fungal research, and billions of dollars spent developing treatments that may ultimately be traced to systems defined herein. Such a decision is scientifically unforgivable and should be investigated. This author has seen the original science- it exists. 

Thus, this author is content to leave the issues to the verdict of history
________________________________________
References
1. Acharya, N., et al. (2017). Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences, 114(19), 5005–5010. https://doi.org/10.1073/pnas.1612177114 
2. Agarwal, S., et al. (2014). Arachidonic acid affects biofilm formation and PGE₂ level in Candida albicans and non-albicans species in presence of subinhibitory concentration of fluconazole and terbinafine. Brazilian Journal of Infectious Diseases, 18(3), 287–293. https://doi.org/10.1016/j.bjid.2013.09.006 
3. Akula, S. T., et al. (2021). Antifungal efficacy of lauric acid and caprylic acid - Derivatives of virgin coconut oil against Candida albicans. Biomedical and Biotechnology Research Journal, 5(2), 229-234.
4. Alem, M. A., & Douglas, L. J. (2005). Prostaglandin production during growth of Candida albicans biofilms. Journal of Medical Microbiology, 54(11), 1001–1005. https://doi.org/10.1099/jmm.0.46172-0 
5. Allen, J. H., de Moore, G. M., Heddle, R., & Twartz, J. C. (2004). Cannabinoid hyperemesis: Cyclical hyperemesis in association with chronic cannabis abuse. Gut, 53(11), 1566-1570. https://doi.org/10.1136/gut.2003.036350 
6. Ali, A., Jadhav, A., Jangid, P., et al. (2018). The human muscarinic acetylcholine receptor antagonist, dicyclomine targets signal transduction genes and inhibits the virulence factors in the human pathogen, Candida albicans. The Journal of Antibiotics, 71, 456–466. https://doi.org/10.1038/s41429-017-0009-8
7. Al-Joubori, T. A., Mahdi, M. A., Ahmed, A. M. (2026). Comparative In Vitro Antifungal Activity of Virgin Coconut Oil and Conventional Antifungal Agents Against Fluconazole-Resistant Candida albicans Isolated from Vaginal Infections. Muthanna Medical Journal 13(2):93-98.
8. Alonso-Monge, R., Gresnigt, M. S., Román, E., Hube, B., & Pla, J. (2021). Candida albicans colonization of the gastrointestinal tract: A double-edged sword. PLoS Pathogens, 17(7), Article e1009710. https://doi.org/10.1371/journal.ppat.1009710 
9. Arc Institute. (2025). Evo 2: Genome modeling and design across all domains of life. bioRxiv. https://doi.org/10.1101/2025.02.18.638918  [Subsequently published in Nature, 2026 as https://doi.org/10.1038/s41586-026-10176-5 ]
10. Askew, C., Sellam, A., Epp, E., Hogues, H., Mullick, A., Nantel, A., & Whiteway, M. (2009). Transcriptional regulation of carbohydrate metabolism in the human pathogen Candida albicans. PLoS Pathogens, 5(10), Article e1000612. https://doi.org/10.1371/journal.ppat.1000612 
11. Augustyniak, D., Kramarska, E., Mackiewicz, P., Olszak, T., & Weber-Dabrowska, B. (2021). Mammalian neuropeptides as modulators of microbial infections: Their dual role in defense versus virulence and pathogenesis. International Journal of Molecular Sciences, 22(7), Article 3658. https://doi.org/10.3390/ijms22073658 
12. Bader, O., Krauke, Y., & Hube, B. (2008). Processing of predicted substrates of fungal Kex2 proteinases from Candida albicans, C. glabrata, Saccharomyces cerevisiae and Pichia pastoris. BMC Microbiology, 8, Article 116. https://doi.org/10.1186/1471-2180-8-116 
13. Bahraminia, M., Cui, S., Zhang, Z., Semlali, A., Le Roux, É., Giroux, K.-A., Lajoie, C., Béland, F., & Rouabhia, M. (2024). Effect of cannabidiol (CBD), a cannabis plant derivative, against Candida albicans growth and biofilm formation. Canadian Journal of Microbiology. https://doi.org/10.1139/cjm-2024-0034 
14. Ballou, E. R., Avelar, G. M., Childers, D. S., Mackie, J., Bain, J. M., Wagener, J., et al. (2016). Lactate signalling regulates fungal β-glucan masking and immune evasion. Nature Microbiology, 2, Article 16238. https://doi.org/10.1038/nmicrobiol.2016.238 
15. Barelle, C. J., Priest, C. L., Maccallum, D. M., Gow, N. A. R., Odds, F. C., & Brown, A. J. P. (2006). Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cellular Microbiology, 8(6), 961–971. https://doi.org/10.1111/j.1462-5822.2005.00676.x 
16. Barnett, M., Meister, L., & Rainey, P. B. (2025). Experimental evolution of evolvability. Science. https://doi.org/10.1126/science.adr2756 
17. Bartelli, T. F., Bruno, D. C. F., & Briones, M. R. S. (2018). Evidence for mitochondrial genome methylation in the yeast Candida albicans: A potential novel epigenetic mechanism affecting adaptation and pathogenicity? Frontiers in Genetics, 9, Article 166. https://doi.org/10.3389/fgene.2018.00166 
18. Barbosa, A. H., Mendes, F. R. N., Silva, A. P. M., et al. (2020). Candida albicans adaptation on simulated human body fluids under different pH. Microorganisms, 8(4), 511. https://doi.org/10.3390/microorganisms8040511 
19. Berger, A., & Loutre, M. F. (1991). Insolation values for the climate of the last 10 million years. Quaternary Science Reviews, 10(4), 297–317. https://doi.org/10.1016/0277-3791(91)90033-Q 
20. Bergner, A. G. N., Trauth, M. H., & Bookhagen, B. (2003). Magnitude of precipitation/evaporation changes in the Naivasha Basin (Kenya) during the last 150 kyrs. Global and Planetary Change, 36(1–2), 117–135. https://doi.org/10.1016/S0921-8181(02)00178-9 
21. Bhatt, S., et al. (2024). Na⁺/K⁺-ATPase: More than an electrogenic pump. International Journal of Molecular Sciences, 25(11), Article 6122. https://doi.org/10.3390/ijms25116122 
22. Bramley, T. A., Menzies, G. S., Williams, R. J., Adams, D. J., & Kinsman, O. S. (1990). Specific, high-affinity binding sites for human luteinizing hormone (hLH) and human chorionic gonadotrophin (hCG) in Candida species. Biochemical and Biophysical Research Communications, 167(3), 1050–1056.
23. Bramley, T. A., Menzies, G. S., Williams, R. J., Kinsman, O. S., & Adams, D. J. (1991). Binding sites for LH in Candida albicans: Comparison with the mammalian corpus luteum LH receptor. Journal of Endocrinology, 130(1), 177–190.
24. Brogden, K. A., Guthmiller, J. M., Salzet, M., & Zasloff, M. (2005). The nervous system and innate immunity: The neuropeptide connection. Nature Immunology, 6(6), 558–564. https://doi.org/10.1038/ni1209 
25. Brown, F., Harris, J., Leakey, R., & Walker, A. (1985). Early Homo erectus skeleton from west Lake Turkana, Kenya. Nature, 316(6031), 788–792. https://doi.org/10.1038/316788a0 
26. Brown, V., Sexton, J. A., & Johnston, M. (2006). A glucose sensor in Candida albicans. Eukaryotic Cell, 5(10), 1726–1737. https://doi.org/10.1128/EC.00186-06 
27. Buck, A. H., Coakley, G., Simbari, F., et al. (2014). Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. Nature Communications, 5, Article 5488. https://doi.org/10.1038/ncomms6488 
28. Butler, G., et al. (2009). Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature, 459(7247), 657–662. https://doi.org/10.1038/nature08064 
29. Cai, Q., Qiao, L., Wang, M., et al. (2018). Plants send small RNAs in extracellular vesicles to fungal pathogen to silence virulence genes. Science, 360(6393), 1126–1129. https://doi.org/10.1126/science.aar4142 
30. Castro, M., Ralston, N. V. C., Morgenthaler, T. I., Rohrbach, M. S., & Limper, A. H. (1994). Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components. Infection and Immunity, 62(8), 3138–3145. https://doi.org/10.1128/iai.62.8.3138-3145.1994  (PMC302938)
31. Chen, Y., et al. (2022). Integrative functional analysis uncovers metabolic differences between Candida species. Communications Biology, 5, Article 955.
32. Chen, Y., et al. (2025). Coordinated regulation of pH alkalinization by two transcription factors promotes fungal commensalism and pathogenicity. Nature Communications, 16, Article 7512. https://doi.org/10.1038/s41467-025-62953-x 
33. Cheng, S. C., van de Veerdonk, F. L., Smeekens, S., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B. J., & Netea, M. G. (2010). Candida albicans dampens host defense by downregulating IL-17 production. The Journal of Immunology, 185(4), 2450–2457. https://doi.org/10.4049/jimmunol.1000756 
34. Chorowicz, J. (2005). The East African rift system. Journal of African Earth Sciences, 43(1–3), 379–410. https://doi.org/10.1016/j.jafrearsci.2005.07.019 
35. Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. The Lancet, 370(9600), 1706–1713.
36. Craddock, J. (2013). Unpublished clinical summary and article recollection. Personal archive. [Cited as: Craddock, 2013.]
37. Craddock, J (2026). Acute Hemodynamic Decompensation Following Routine Phlebotomy in a Patient with Chronic Volume Dysregulation: A Five-Week Longitudinal Provocation Sequence. April 2026. https://doi.org/10.5281/zenodo.19462704 
38. Craddock, J. (2026). Phase 5 of a 31-Year Managed Symbiont Progression - A Longitudinal Case Study Interpreted Through the Biochemical Computer Framework. April 2026. https://doi.org/10.5281/zenodo.19560800 [Cited as Craddock Case Studies]
39. Craddock, J. (2026). Terminal onset diabetes insipidus with candidiasis Majeure: A longitudinal case study. jimcraddock.com. April 2026. https://doi.org/10.5281/zenodo.19702341  [Cited as: Craddock Case Studies.]
40. Craddock, J. The Arachidonic Acid Branch Point: External Empirical Confirmation. Architect Report AM#022. Redacted Science Research Initiative. https://doi.org/10.5281/zenodo.19983864  [Cited as: Craddock, AA Branch Point.]
41. Craddock, J. Candida albicans as a Biochemical Computer: Cross-Kingdom Signaling, Parasexual Reproduction, and Genetic Foundations of a Unique Fungal Symbiont. Zenodo. https://doi.org/10.5281/zenodo.19337526  [Cited as: Craddock, Biochemical Computer.]
42. Craddock, J. The Pan-Mammalian Coevolution Hypothesis. Zenodo. https://doi.org/10.5281/zenodo.19643601  [Cited as: Craddock, Pan-Mammalian.]
43. Craddock, J. They Looked. They Were Right. They Were Destroyed.: An Exposé of the Institutional Mechanisms by Which a 1960s Research Corridor Was Dismantled. Zenodo. https://doi.org/10.5281/zenodo.19393803  [Cited as: Craddock, Exposé.]
44. Craddock, J. Redacted Science [Book]. Distributed via IPFS, Nostr, redactedscience.org. CID: bafybeidq7u7xbs526xvml6s6pbwq43rh7k5bzdrgkwlovwhw5oq2vhdrja [Cited as: Craddock, Redacted Science.]
45. Crawford, G. W. (2006). East Asian plant domestication. In M. T. Stark (Ed.), Archaeology of Asia (pp. 77–95). Blackwell.
46. Cuellar-Rufino, S., et al. (2022). Iodine induces toxicity against Candida albicans and Candida glabrata through oxidative stress. Iranian Journal of Microbiology, 14(2), 260–267. https://doi.org/10.18502/ijm.v14i2.9195 
47. Cugini, C., et al. (2007). Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Molecular Microbiology, 65(4), 896–906.
48. Cunnane, S. C. (2005). Survival of the fattest: The key to human brain evolution. World Scientific Publishing.
49. Danhof, H. A., et al. (2016). Robust extracellular pH modulation by Candida albicans during growth in carboxylic acids. mBio, 7(6), Article e01646-16. https://doi.org/10.1128/mBio.01646-16 
50. De Petrocellis, L., et al. (1999). The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences, 96(14), 8369–8374.
51. Deino, A. L., Kingston, J. D., Glen, J. M., Edgar, R. K., & Hill, A. (2006). Precessional forcing of lacustrine sedimentation in the Late Cenozoic Chemeron Basin, Central Kenya Rift, and calibration of the Gauss/Matuyama boundary. Earth and Planetary Science Letters, 247(1–2), 41–60. https://doi.org/10.1016/j.epsl.2006.04.009 
52. Deocampo, D. M., & Renaut, R. W. (2022). Mineral precipitation and hydrochemical evolution through evaporitic processes in soda brines (East African Rift Valley). Chemical Geology, 613, Article 121153. https://doi.org/10.1016/j.chemgeo.2022.121153 
53. Deva, R., Ciccoli, R., Schewe, T., Kock, J. L. F., & Nigam, S. (2000). Arachidonic acid stimulates cell growth and forms a novel oxygenated metabolite in Candida albicans. Biochimica et Biophysica Acta, 1486(2–3), 299–311.
54. Dezieck, L., Hafez, Z., Conicella, A., Bhambhvani, H., Gould, O., Nusbaum, J., & Halpert, J. (2017). Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: A case series. Clinical Toxicology, 55(8), 908-913. https://doi.org/10.1080/15563650.2017.1324166 
55. Di Marzo, V. (2006). Endocannabinoids: Synthesis and degradation. Reviews of Physiology, Biochemistry and Pharmacology, 160, 1–24.
56. Di Marzo, V., & Piscitelli, F. (2015). The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics, 12(4), 692–698.
57. Dichtl, K., et al. (2010). Farnesol misplaces tip-localized Rho proteins and inhibits cell wall integrity signaling in Aspergillus fumigatus. Molecular Microbiology, 76(5), 1191–1204.
58. Dumeaux, V., Massahi, S., Bettauer, V., et al. (2023). Candida albicans exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds. eLife, 12, Article e81406.
59. Dunkel, N., Hertlein, T., Franz, R., et al. (2013). Roles of different peptide transporters in nutrient acquisition in Candida albicans. Eukaryotic Cell, 12(4), 520–528. https://doi.org/10.1128/EC.00008-13 
60. Ebinger, C. J., et al. (2000). Rift deflection, migration, and propagation: Linkage of the Ethiopian and Eastern rifts, Africa. GSA Bulletin, 112(2), 163–176.
61. Eldredge, N., & Gould, S. J. (1972). Punctuated equilibria: An alternative to phyletic gradualism. In T. J. M. Schopf (Ed.), Models in paleobiology (pp. 82–115). Freeman, Cooper.
62. Elijovich, F., Weinberger, M. H., Anderson, C. A. M., Appel, L. J., Bursztyn, M., Cook, N. R., Dart, R. A., Newton-Cheh, C. H., Sacks, F. M., & Laffer, C. L. (2016). Salt sensitivity of blood pressure: A scientific statement from the American Heart Association. Hypertension, 68(3), e7–e46. https://doi.org/10.1161/HYP.0000000000000047 
63. Elphick, M. R. (2012). The evolution and comparative neurobiology of endocannabinoid signaling. Philosophical Transactions of the Royal Society B, 367(1607), 3201–3215. https://doi.org/10.1098/rstb.2011.0394 
64. Elphick, M. R., Satou, Y., & Satoh, N. (2003). The invertebrate ancestry of endocannabinoid signaling: An orthologue of vertebrate cannabinoid receptors in the urochordate Ciona intestinalis. Gene, 302(1–2), 95–101. https://doi.org/10.1016/S0378-1119(02)01094-6 
65. Elson, S. L., Noble, S. M., Solis, N. V., Filler, S. G., & Johnson, A. D. (2009). An RNA transport system in Candida albicans regulates hyphal morphology and invasive growth. PLoS Genetics, 5(9), Article e1000664. https://doi.org/10.1371/journal.pgen.1000664 
66. Erb-Downward, J. R., & Noverr, M. C. (2007). Characterization of prostaglandin E₂ production by Candida albicans. Infection and Immunity, 75(7), 3498–3505. https://doi.org/10.1128/IAI.00232-07 
67. Forman, B. M., et al. (1995). Identification of a nuclear receptor that is activated by farnesol metabolites. Cell, 81(5), 687–693.
68. Fredriksson, R., et al. (2003). The G-protein-coupled receptors in the human genome form five main families. Molecular Pharmacology, 63(6), 1256–1272.
69. Freire-Benéitez, V., Price, R. J., & Buscaino, A. (2016). Candida albicans repetitive elements display epigenetic diversity and plasticity. Scientific Reports, 6, Article 22989. https://doi.org/10.1038/srep22989 
70. Fuss, J., Steinle, J., Bindila, L., et al. (2015). A runner's high depends on cannabinoid receptors in mice. Proceedings of the National Academy of Sciences, 112(42), 13105–13108. https://doi.org/10.1073/pnas.1514996112 
71. Garcin, Y., Junginger, A., Melnick, D., Olago, D., Strecker, M. R., & Trauth, M. H. (2009). Late Pleistocene–Holocene rise and collapse of Lake Suguta, northern Kenya Rift. Quaternary Science Reviews, 28(9–10), 911–925. https://doi.org/10.1016/j.quascirev.2008.11.001 
72. Garrahan, P. J., & Glynn, I. M. (1966). Driving the sodium pump backwards to form adenosine triphosphate. Nature, 211, 1414–1415. https://doi.org/10.1038/2111414a0 
73. Gates, E. J., et al. (2026). Farnesol, the farnesol pathway, and the immune-gut-brain axis. Frontiers in Pharmacology.
74. GSE303922. (2025). Transcriptomic Evidence of Acquired Cannabis Hypersensitivity in Cannabinoid Hyperemesis Syndrome. Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303922 
75. Gc, J. B., et al. (2023). Allosteric modulation of α1β3γ2 GABA-A receptors by farnesol through the neurosteroid sites. Neuropharmacology, 224, Article 109342.
76. Gómez-Gaviria, M., et al. (2023). Multi-omics profiling of Candida albicans grown on solid versus liquid media. Microorganisms, 11(12), Article 2831.
77. Grahl, N., Shepardson, K. M., Chung, D., & Cramer, R. A. (2012). Hypoxia and fungal pathogenesis: To air or not to air? Eukaryotic Cell, 11(5), 560–570. https://doi.org/10.1128/EC.00031-12 
78. Guan, G., Tao, L., Li, C., et al. (2023). Glucose depletion enables Candida albicans mating independently of the epigenetic white-opaque switch. Nature Communications, 14, 2067. https://doi.org/10.1038/s41467-023-37755-8 
79. Gupta, A., Zaman, L., Strobel, H. M., Gallie, J., Burmeister, A. R., Kerr, B., Tamar, E. S., Kishony, R., & Meyer, J. R. (2022). Host–parasite coevolution promotes innovation through deformations in fitness landscapes. eLife, 11, e76162. https://doi.org/10.7554/eLife.76162 
80. Halder, L. D., Babych, S., Palme, D. I., et al. (2022). Candida albicans Induces Cross-Kingdom miRNA Trafficking in Human Monocytes To Promote Fungal Growth. mBio, 13(1), e03563-21. https://doi.org/10.1128/mbio.03563-21
81. Hall, R. A., et al. (2010). CO₂ acts as a signalling molecule in populations of the fungal pathogen Candida albicans. PLoS Pathogens, 6(11), Article e1001193.
82. Harmand, S., et al. (2015). 3.3-million-year-old stone tools from Lomekwi 3, West Turkana, Kenya. Nature, 521(7552), 310–315. https://doi.org/10.1038/nature14464 
83. Head, M. G., et al. (2014). A systematic analysis of funding awarded for mycology research to institutions in the UK, 1997–2010. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(14)70799-5 
84. Hia, F., Wu, Y., Yoshinaga, M., et al. (2026). Human DHX29 detects nonoptimal codon usage to regulate mRNA stability. Science. https://doi.org/10.1126/science.adw0288 
85. Ho, J., et al. (2021). Candidalysin is a potent trigger of alarmin and antimicrobial peptide release in epithelial cells. Cells, 9(3), Article 699. https://doi.org/10.3390/cells9030699 
86. Izzo, A. A., Capasso, F., Costagliola, A., et al. (2003). An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology, 125(3), 765-774. https://doi.org/10.1016/S0016-5085(03)00892-8 
87. Hogan, D. A., Vik, A., & Kolter, R. (2004). A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Molecular Microbiology, 54(5), 1212–1223.
88. Hornby, J. M., et al. (2001). Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Applied and Environmental Microbiology, 67(7), 2982–2992.
89. Jablonski, N. G., & Chaplin, G. (2000). The evolution of human skin coloration. Journal of Human Evolution, 39(1), 57–106. https://doi.org/10.1006/jhev.2000.0403 
90. Jackson, A. P., et al. (2009). Comparative genomics of the fungal pathogens Candida dubliniensis and Candida albicans. Genome Research, 19(12), 2231–2244. https://doi.org/10.1101/gr.097501.109 
91. Jadhav, A., et al. (2017). The dietary food components capric acid and caprylic acid inhibit virulence factors in Candida albicans through multitargeting. Journal of Medicinal Food, 20(11), 1083-1090.
92. Jiang, H. E., et al. (2016). Ancient Cannabis burial shroud in a Central Eurasian Cemetery. Economic Botany, 70(3), 213–221. https://doi.org/10.1007/s12231-016-9351-1 
93. Johanson, D. C., & White, T. D. (1979). A systematic assessment of early African hominids. Science, 203(4378), 321–330.
94. Joo, J. H., et al. (2009). Molecular mechanisms involved in farnesol-induced apoptosis. Biochimica et Biophysica Acta, 1793(11), 1721–1732.
95. Joo, J. H., et al. (2010). Candida albicans quorum-sensing molecule tyrosol modulates neutrophil activity and host immune responses. Microbiology, 156(Pt 12), 3854–3864.
96. Johnson, T. C., et al. (2016). A progressively wetter climate in southern East Africa over the past 1.3 million years. Nature, 537(7619), 220–224. https://doi.org/10.1038/nature19065 
97. Junginger, A., & Trauth, M. H. (2013). Hydrological constraints of paleo-Lake Suguta in the Northern Kenya Rift during the African Humid Period (15–5 ka BP). Global and Planetary Change, 111, 174–188.
98. Karkowska-Kuleta, J., et al. (2025). Host cell responses to Candida albicans biofilm-derived extracellular vesicles. Frontiers in Cellular and Infection Microbiology, 14, Article 1499461. https://doi.org/10.3389/fcimb.2024.1499461 
99. Kinsman, O. S., Pitblado, K., & Coulson, C. J. (1988). Effect of mammalian steroid hormones and luteinizing hormone on the germination of Candida albicans and implications for vaginal candidosis. Mycoses, 31(12), 617–626.
100. Kong, E. F., et al. (2017). Commensal protection of Staphylococcus aureus against antimicrobials by Candida albicans biofilm matrix. mBio, 8(4), Article e01415-17.
101. Krombach, S., et al. (2025). A co-evolved peptide-GPCR system senses host entry to drive fungal infection. bioRxiv. https://doi.org/10.1101/2025.09.26.678928 
102. Kumamoto, C. A. (2011). Inflammation and gastrointestinal Candida colonization. Current Opinion in Microbiology, 14(4), 386–391.
103. Kumwenda, P., Cottier, F., Hendry, A. C., et al. (2022). Estrogen promotes innate immune evasion of Candida albicans through inactivation of the alternative complement system. Cell Reports, 38(1), Article 110183.
104. Kundu, G., & Noverr, M. C. (2011). Exposure to host or fungal PGE₂ abrogates protection following immunization with Candida-pulsed dendritic cells. Medical Mycology, 49(4), 380–394. https://doi.org/10.3109/13693786.2010.532514 
105. Kussell, E., & Leibler, S. (2005). Phenotypic diversity, population growth, and information in fluctuating environments. Science, 309(5743), 2075–2078. https://doi.org/10.1126/science.1114383 
106. Kutzbach, J. E., & Street-Perrott, F. A. (1985). Milankovitch forcing of fluctuations in the level of tropical lakes from 18 to 0 kyr BP. Nature, 317(6033), 130–134. https://doi.org/10.1038/317130a0 
107. Lachat, J., et al. (2022). Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage. Nature Communications, 13, Article 3781. https://doi.org/10.1038/s41467-022-31237-z 
108. Leakey, L. S. B. (1959). A new fossil skull from Olduvai. Nature, 184(4685), 491–493.
109. Leonhardt, I., Spielberg, S., Weber, M., et al. (2015). The fungal quorum-sensing molecule farnesol activates innate immune cells but suppresses cellular adaptive immunity. mBio, 6(2), Article e00143-15. https://doi.org/10.1128/mBio.00143-15 
110. Leshem, M. (2009). Biobehavior of the human love of salt. Neuroscience & Biobehavioral Reviews, 33(1), 1–17. https://doi.org/10.1016/j.neubiorev.2008.07.007 
111. Li, H. L. (1974). An archaeological and historical account of cannabis in China. Economic Botany, 28(4), 437–448. https://doi.org/10.1007/BF02862859 
112. Li, S., He, F., Wen, H., et al. (2017). Low salinity affects cellularity, DNA methylation, and mRNA expression of igf1 in the liver of half smooth tongue sole (Cynoglossus semilaevis). Fish Physiology and Biochemistry, 43(6), 1587–1602. https://doi.org/10.1007/s10695-017-0395-7 
113. Li, Y., et al. (2018). Promising antifungal targets against Candida albicans based on ion homeostasis. Frontiers in Cellular and Infection Microbiology, 8, Article 286. https://doi.org/10.3389/fcimb.2018.00286 
114. Lin, J., & Filler, S. G. (2025). Host targets of candidalysin. PLoS Pathogens, 21(6), Article e1013284. https://doi.org/10.1371/journal.ppat.1013284 
115. Lin, J., et al. (2024). Global fungal-host interactome mapping identifies host targets of candidalysin. Nature Communications, 15, Article 1757. https://doi.org/10.1038/s41467-024-46141-x 
116. Lionakis, M. S., Samonis, G., & Kontoyiannis, D. P. (2008). Endocrine and metabolic manifestations of invasive fungal infections and systemic antifungal treatment. Mayo Clinic Proceedings, 83(9), 1046–1060. https://doi.org/10.4065/83.9.1046 
117. Loose, D. S., & Feldman, D. (1981). A corticosteroid binding protein and endogenous ligand in C. albicans indicating a possible steroid-receptor system. Nature, 293(5832), 477–479.
118. Loose, D. S., Schurman, D. J., & Feldman, D. (1982). Characterization of a unique corticosterone-binding protein in Candida albicans. Journal of Biological Chemistry, 257(9), 4925–4930.
119. Lopez, C. M., Wallich, R., Riesbeck, K., Skerka, C., & Zipfel, P. F. (2014). Candida albicans uses the surface protein Gpm1 to attach to human endothelial cells and to keratinocytes via the adhesive protein vitronectin. PLoS ONE, 9(3), Article e90796.
120. Lorenz, M. C., Bender, J. A., & Fink, G. R. (2004). Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryotic Cell, 3(5), 1076–1087. https://doi.org/10.1128/EC.3.5.1076-1087.2004 
121. Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 16(12), 705–718. https://doi.org/10.1038/nrn4036 
122. Lyons, R. P., et al. (2015). Continuous 1.3-million-year record of East African hydroclimate, and implications for patterns of evolution and biodiversity. Proceedings of the National Academy of Sciences, 112(51), 15568–15573. https://doi.org/10.1073/pnas.1512864112 
123. Markey, L., et al. (2020). Colonization with the commensal fungus Candida albicans perturbs the gut-brain axis through dysregulation of endocannabinoid signaling. Psychoneuroendocrinology, 121, Article 104808. https://doi.org/10.1016/j.psyneuen.2020.104808 
124. Martínez-López, R., et al. (2022). Candida albicans hyphal extracellular vesicles are different from yeast ones, carrying an active proteasome complex and showing a different role in host immune response. mSphere, 7(3), Article e00098-22. https://doi.org/10.1128/msphere.00098-22 
125. Masachis, S., et al. (2016). A fungal pathogen secretes plant alkalinizing peptides to increase infection. Nature Microbiology, 1, Article 16043.
126. Maslin, M. A., Brierley, C. M., Milner, A. M., Shultz, S., Trauth, M. H., & Wilson, K. E. (2014). East African climate pulses and early human evolution. Quaternary Science Reviews, 101, 1–17. https://doi.org/10.1016/j.quascirev.2014.06.012 
127. Maslin, M. A., Shultz, S., & Trauth, M. H. (2015). A synthesis of the theories and concepts of early human evolution. Philosophical Transactions of the Royal Society B, 370(1663), Article 20140064. https://doi.org/10.1098/rstb.2014.0064 
128. Maslin, M. A., & Trauth, M. H. (2009). Plio-Pleistocene East African pulsed climate variability and its influence on early human evolution. In F. E. Grine, J. G. Fleagle, & R. E. Leakey (Eds.), The first humans — Origin and early evolution of the genus Homo. Springer. https://doi.org/10.1007/978-1-4020-9980-9_13 
129. McManus, B. A., et al. (2008). Multilocus sequence typing reveals that the population structure of Candida dubliniensis is significantly less divergent than that of Candida albicans. Journal of Clinical Microbiology, 46(2), 652–664. https://doi.org/10.1128/JCM.01574-07 
130. McPartland, J. M., et al. (2006). Cannabinoid receptors in invertebrates. Journal of Evolutionary Biology, 19(2), 366–373. https://doi.org/10.1111/j.1420-9101.2005.01028.x 
131. McPartland, J. M., Hegman, W., & Long, T. (2019). Cannabis in Asia: Its center of origin and early cultivation, based on a synthesis of subfossil pollen and archaeobotanical studies. Vegetation History and Archaeobotany, 28(6), 691–702. https://doi.org/10.1007/s00334-019-00731-8 
132. Metzger, D. C. H., & Schulte, P. M. (2018). The DNA methylation landscape of stickleback reveals patterns of sex chromosome evolution and effects of environmental salinity. Genome Biology and Evolution, 10(3), 775–785. https://doi.org/10.1093/gbe/evy034 
133. Meltzer, A. C., et al. (2025). Transcriptomic Evidence of Acquired Cannabis Hypersensitivity in Cannabinoid Hyperemesis Syndrome. Research Square (preprint). https://doi.org/10.21203/rs.3.rs-8116530/v1 
134. Midkiff, J., Borochoff-Porte, N., White, D., & Johnson, D. I. (2011). Small molecule inhibitors of the Candida albicans budded-to-hyphal transition act through multiple signaling pathways. PLoS ONE, 6(9), Article e25395. https://doi.org/10.1371/journal.pone.0025395 
135. Mishra, P. K., Baum, M., & Carbon, J. (2011). DNA methylation regulates phenotype-dependent transcriptional activity in Candida albicans. Proceedings of the National Academy of Sciences, 108(29), 11965–11970. https://doi.org/10.1073/pnas.1109631108 
136. Mitchell, A., et al. (2009). Adaptive prediction of environmental changes by microorganisms. Nature, 460, 220–224. https://doi.org/10.1038/nature08112 
137. Mohammed, F., Panchoo, K., Engeler, D., & Daniel, H. (2013). Compulsive showering and marijuana use: The cannabis hyperemesis syndrome. Journal of Clinical Medicine Research, 5(3), 243-245. https://doi.org/10.14740/jocmr1407 
138. Moyes, D. L., et al. (2016). Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature, 532(7597), 64–68. https://doi.org/10.1038/nature17625 
139. Moyes, D. L., et al. (2019). Candidalysin activates innate epithelial immune responses via epidermal growth factor receptor. Nature Communications, 10, Article 2297. https://doi.org/10.1038/s41467-019-09915-2 
140. Murphy, S. K., Itchon-Ramos, N., Vber, Z., et al. (2018). Cannabinoid exposure and altered DNA methylation in rat and human sperm. Epigenetics, 13(12), 1208–1221. https://doi.org/10.1080/15592294.2018.1554521 
141. Naglik, J. R., et al. (2022). Pathogenesis and virulence of Candida albicans. Virulence, 13(1), 1–45. https://doi.org/10.1080/21505594.2021.2019950 
142. Navarathna, D. H., Nickerson, K. W., et al. (2007). Farnesol modulates Candida albicans morphogenesis and host immune interactions. FEMS Yeast Research.
143. NCD Risk Factor Collaboration (NCD-RisC). (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1 
144. Nickerson, K. W., et al. (2023). Physiological adventures in Candida albicans: Farnesol and ubiquinones. Microbiology and Molecular Biology Reviews. https://doi.org/10.1128/mmbr.00081-22 
145. Nile, C. J., et al. (2018). Repurposing pilocarpine hydrochloride for treatment of Candida albicans infections. mSphere, 3(6), Article e00689-18.
146. Nobile, C. J., et al. (2021). Evolution of the complex transcription network controlling biofilm formation in Candida species. eLife, 10, Article e64682. https://doi.org/10.7554/eLife.64682 
147. Noll, A., et al. (2025). Candida albicans biofilm extracellular vesicles deliver candidalysin to epithelial cell membranes and induce host cell responses. Infection and Immunity. https://doi.org/10.1128/iai.00404-24 
148. Noverr, M. C., & Huffnagle, G. B. (2004). Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infection and Immunity, 72(11), 6206–6210.
149. Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J., & Huffnagle, G. B. (2001). Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infection and Immunity, 69(5), 2957–2963. https://doi.org/10.1128/IAI.69.5.2957-2963.2001 
150. Ost, K. S., & Round, J. L. (2023). Commensal fungi in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology, 20, 723–734.
151. Pacioni, G., Rapino, C., Zarivi, O., et al. (2015). Truffles contain endocannabinoid metabolic enzymes and anandamide. Phytochemistry, 110, 104–110. https://doi.org/10.1016/j.phytochem.2014.11.012 
152. Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27(1), 73–100.
153. Pandey, R., et al. (2009). Endocannabinoids and immune regulation. Pharmacological Research, 60(2), 85–92. https://doi.org/10.1016/j.phrs.2009.03.019 
154. Peres da Silva, R., et al. (2022). The RNA content of fungal extracellular vesicles: At the "cutting-edge" of pathophysiology regulation. Cells, 11(14), Article 2235. https://doi.org/10.3390/cells11142235 
155. Perestrelo, R., et al. (2020). Candida species (volatile) metabotyping through advanced comprehensive two-dimensional gas chromatography. Microorganisms, 8(12), Article 1911.
156. Peroumal, D., et al. (2022). Commensal fungus Candida albicans maintains a long-term mutualistic relationship with the host to modulate gut microbiota and metabolism. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02462-22 
157. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. https://doi.org/10.1038/sj.bjp.0707442 
158. Petrie, K. L., Palmer, N. D., Johnson, D. T., Medina, S. J., Yan, S. J., Li, V., Burmeister, A. R., et al. (2018). Destabilizing mutations encode nongenetic variation that drives evolutionary innovation. Science, 359(6383), 1542–1545. https://doi.org/10.1126/science.aar1954 
159. Porquier, A., et al. (2023). A fungal RNA-dependent RNA polymerase is a novel player in plant infection and cross-kingdom RNA interference. PLoS Pathogens, 19(12), Article e1011885. https://doi.org/10.1371/journal.ppat.1011885 
160. Potts, R. (1998). Variability selection in hominid evolution. Evolutionary Anthropology, 7(3), 81–96.
161. Pradhan, A., Avelar, G. M., Bain, J. M., Childers, D. S., Larcombe, D. E., Netea, M. G., et al. (2018). Hypoxia promotes immune evasion by triggering β-glucan masking on the Candida albicans cell surface via mitochondrial and cAMP-protein kinase A signaling. mBio, 9(6), Article e01318-18. https://doi.org/10.1128/mBio.01318-18 
162. Rajendran, R., Borghi, E., Falleni, M., et al. (2015). Acetylcholine protects against Candida albicans infection by inhibiting biofilm formation and promoting hemocyte function in a Galleria mellonella infection model. Eukaryotic Cell, 14(8), 834–844.
163. Ramos, J., et al. (2022). Candida albicans potassium transporters. International Journal of Molecular Sciences, 23(9), Article 4884. https://doi.org/10.3390/ijms23094884 
164. Ren, M., Tang, Z., Wu, X., et al. (2019). The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs. Science Advances, 5(6), Article eaaw1391. https://doi.org/10.1126/sciadv.aaw1391 
165. Reuß, O., & Morschhäuser, J. (2006). A family of oligopeptide transporters is required for growth of Candida albicans on proteins. Molecular Microbiology, 60(3), 795–812. https://doi.org/10.1111/j.1365-2958.2006.05136.x 
166. Ribas, C. R., Rymovicz, A. U. M., Rosa, R. T., et al. (2019). Increments in virulence of Candida albicans induced by androgenic anabolic steroids. Steroids, 152, Article 108501. https://doi.org/10.1016/j.steroids.2019.108501 
167. Richardson, J. P., et al. (2018). Processing of Candida albicans Ece1p is critical for candidalysin maturation and fungal virulence. mBio, 9(1), Article e02178-17. https://doi.org/10.1128/mBio.02178-17 
168. Robinson, J. D., Hall, E. S., & Dunham, P. B. (1977). Reversal of the Na-K pump and apparent affinity for intracellular potassium. Nature, 269, 165–167. https://doi.org/10.1038/269165a0 
169. Rodaki, A., Bohovych, I. M., Enjalbert, B., Young, T., Odds, F. C., Gow, N. A. R., & Brown, A. J. P. (2009). Glucose promotes stress resistance in the fungal pathogen Candida albicans. Molecular Biology of the Cell, 20(22), 4845–4855.
170. Rodriguez, R. J., & Redman, R. S. (2008). More than 400 million years of evolution and some plants still can't make it on their own: Plant stress tolerance via fungal symbiosis. Journal of Experimental Botany, 59(5), 1109–1114. https://doi.org/10.1093/jxb/erm342 
171. Rogers, A. R., Islam, M. T., Brand, C. M., & Webster, T. H. (2026). Human ancestors interbred with two distinct populations of distant relatives. bioRxiv. https://doi.org/10.64898/2026.03.22.713509 
172. Romo, J. A., & Kumamoto, C. A. (2020). On commensalism of Candida. Journal of Fungi, 6(1), Article 16.
173. Roullet, J. B., et al. (1999). Farnesol inhibits L-type Ca²⁺ channels in vascular smooth muscle cells. Journal of Biological Chemistry, 274(36), 25439–25446.
174. Rudenko, S. I. (1970). Frozen tombs of Siberia: The Pazyryk burials of Iron Age horsemen. University of California Press.
175. Rudolph, A. M. (2009). Congenital Diseases of the Heart: Clinical-Physiological Considerations (3rd ed.). Wiley-Blackwell. https://doi.org/10.1002/9781444311822 
176. Russell, C. M., et al. (2022). The Candida albicans virulence factor candidalysin polymerizes in solution to form membrane pores and damage epithelial cells. eLife, 11, Article e75490. https://doi.org/10.7554/eLife.75490 
177. Russo, E. B., Jiang, H. E., Li, X., et al. (2008). Phytochemical and genetic analyses of ancient cannabis from Central Asia. Journal of Experimental Botany, 59(15), 4171–4182. https://doi.org/10.1093/jxb/ern260 
178. Sabina, J., & Brown, V. (2009). Glucose sensing network in Candida albicans: A sweet spot for fungal morphogenesis. Eukaryotic Cell, 8(9), 1314–1320.
179. Sagar, L. S. R., et al. (2017). Epigenetic determinants of phenotypic plasticity in Candida albicans. Fungal Biology Reviews, 32(1), 10–19. https://doi.org/10.1016/j.fbr.2017.07.002 
180. Sam, A. H., Salem, V., & Ghatei, M. A. (2011). Rimonabant: From RIO to ban. Journal of Obesity, 2011, Article 432607.
181. Schaller, M., et al. (1999). Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. Journal of Investigative Dermatology, 114(4), 712–717.
182. Schlicker, E., & Kathmann, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends in Pharmacological Sciences, 22(11), 565–572.
183. Scholz, C. A., et al. (2007). East African megadroughts between 135 and 75 thousand years ago and bearing on early-modern human origins. Proceedings of the National Academy of Sciences, 104(42), 16416–16421.
184. Schrevens, S., Van Zeebroeck, G., Riedelberger, M., Tournu, H., Kuchler, K., & Van Dijck, P. (2018). Methionine is required for cAMP-PKA-mediated morphogenesis and virulence of Candida albicans. Molecular Microbiology, 108(3), 258–275. https://doi.org/10.1111/mmi.13933 
185. Schrott, R., Murphy, S. K., Modliszewski, J. L., et al. (2020). Reframing cannabis as a negative epigenetic modulator: DNA methylation patterns at the DLGAP2 locus in sperm of men with cannabis exposure. Scientific Reports, 10, Article 9951. https://doi.org/10.1038/s41598-020-67015-w 
186. Schwarz, W., et al. (1991). Conditions for a backward-running Na⁺/K⁺ pump in Xenopus oocytes. Biochimica et Biophysica Acta. https://doi.org/10.1016/0005-2736(91)90062-D 
187. Sellam, A., van Het Hoog, M., Tebbji, F., Beaurepaire, C., Nietzsche, S., Németh, T., et al. (2014). Modeling the transcriptional regulatory network that controls the early hypoxic response in Candida albicans. Eukaryotic Cell, 13(5), 675–690. https://doi.org/10.1128/EC.00292-13 
188. Semighini, C. P., et al. (2006). Farnesol-induced apoptosis in Aspergillus nidulans reveals a possible mechanism for antagonistic interactions between fungi. Molecular Microbiology, 59(3), 753–764.
189. Setiadi, E. R., Doedt, T., Cottier, F., Noffz, C., & Ernst, J. F. (2006). Transcriptional response of Candida albicans to hypoxia: Linkage of oxygen sensing and Efg1p-regulatory networks. Journal of Molecular Biology, 361(3), 399–411. https://doi.org/10.1016/j.jmb.2006.06.040 
190. Shapiro, R. S., et al. (2009). Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Current Biology, 19(8), 621–629.
191. Sharkey, K. A., & Wiley, J. W. (2016). The role of the endocannabinoid system in the brain-gut axis. Gastroenterology, 151(2), 252-266. https://doi.org/10.1053/j.gastro.2016.04.015 
192. Shao, T. Y., et al. (2019). Commensal Candida albicans positively calibrates systemic Th17 immunological responses. Cell Host & Microbe, 25, 404–417.
193. Shchepin, R., et al. (2003). Quorum sensing in Candida albicans: Probing farnesol's mode of action with 40 natural and synthetic farnesol analogs. Chemistry & Biology, 10(8), 743–750.
194. Shivarathri, R., et al. (2019). The Candida albicans biofilm gene circuit modulated at the chromatin level by a recent molecular histone innovation. PLoS Biology, 17(8), Article e3000422. https://doi.org/10.1371/journal.pbio.3000422 
195. Shultz, S., & Maslin, M. A. (2013). Early human speciation, brain expansion and dispersal influenced by African climate pulses. PLoS ONE, 8(10), Article e76750. https://doi.org/10.1371/journal.pone.0076750 
196. Sim-Selley, L. J. (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Critical Reviews in Neurobiology, 15(2), 91-119.
197. Simonetto, D. A., Oxentenko, A. S., Herman, M. L., & Szostek, J. H. (2012). Cannabinoid hyperemesis: A case series of 98 patients. Mayo Clinic Proceedings, 87(2), 114-119. https://doi.org/10.1016/j.mayocp.2011.10.005 
198. Song, S., Chen, P., Shen, X., & Zhang, J. (2025). Adaptive tracking with antagonistic pleiotropy results in seemingly neutral molecular evolution. Nature Ecology & Evolution. https://doi.org/10.1038/s41559-025-02887-1 
199. Sorensen, C. J., DeSanto, K., Borgelt, L., Phillips, K. T., & Monte, A. A. (2017). Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment. Journal of Emergency Medicine, 52(4), 544-551. https://doi.org/10.1016/j.jemermed.2016.09.004 
200. Sterkel, A. K., et al. (2016). Fungal mimicry of a mammalian aminopeptidase disables innate immunity and promotes pathogenicity. Cell Host & Microbe, 19(3), 361–374. https://doi.org/10.1016/j.chom.2016.02.001 
201. Strydom, A., et al. (2010). Effect of inhibitors of arachidonic acid metabolism on prostaglandin E₂ production by Candida albicans and Candida dubliniensis biofilms. Medical Microbiology and Immunology, 200(1), 23–28. https://doi.org/10.1007/s00430-010-0169-7 
202. Sugiura, T., & Waku, K. (2002). Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins, Leukotrienes and Essential Fatty Acids, 66(2–3), 173–192.
203. Sullivan, D. J., Moran, G. P., & Coleman, D. C. (2005). Candida dubliniensis: Ten years on. FEMS Microbiology Letters, 253(1), 9–17. https://doi.org/10.1016/j.femsle.2005.09.015 
204. Synnott, J. M., Guida, A., Mulhern-Haughey, S., Higgins, D. G., & Butler, G. (2010). Regulation of the hypoxic response in Candida albicans. Eukaryotic Cell, 9(11), 1734–1746. https://doi.org/10.1128/EC.00159-10 
205. Szutorisz, H., & Hurd, Y. L. (2016). Epigenetic effects of cannabis exposure. Biological Psychiatry, 79(7), 586–594. https://doi.org/10.1016/j.biopsych.2015.09.014 
206. Tagkopoulos, I., Liu, Y. C., & Tavazoie, S. (2008). Predictive behavior within microbial genetic networks. Science, 320(5881), 1313–1317. https://doi.org/10.1126/science.1154456 
207. Takahashi, M., et al. (2012). Inhibition of Candida mycelia growth by a medium chain fatty acid, capric acid in vitro and its therapeutic efficacy in murine oral candidiasis. Medical Mycology Journal, 53(4), 255-261.
208. Thompson, D. S., et al. (2021). Lineage-specific selection and the evolution of virulence in the Candida clade. Proceedings of the National Academy of Sciences, 118(13), Article e2016818118. https://doi.org/10.1073/pnas.2016818118 
209. Trauth, M. H., et al. (2010). Human evolution in a variable environment: The amplifier lakes of Eastern Africa. Quaternary Science Reviews, 29(23–24), 2981–2988. https://doi.org/10.1016/j.quascirev.2010.07.007 
210. Trauth, M. H., Maslin, M. A., Deino, A., & Strecker, M. R. (2003). East African climate change and orbital forcing during the last 175 kyr BP. Earth and Planetary Science Letters, 206(3–4), 297–313. https://doi.org/10.1016/S0012-821X(02)01105-6 
211. Trauth, M. H., Maslin, M. A., Deino, A., & Strecker, M. R. (2005). Late Cenozoic moisture history of East Africa. Science, 309(5743), 2051–2053. https://doi.org/10.1126/science.1112964 
212. Tucey, T. M., Verma, J., Harrison, P. F., Snelgrove, S. L., Lo, T. L., Scherer, A. K., et al. (2018). Glucose homeostasis is important for immune cell viability during Candida challenge and host survival of systemic fungal infection. Cell Metabolism, 27(5), 988–1006.e7.
213. Turkana Basin Institute. (2021). All about Turkana Boy. turkanabasin.org.
214. Vylkova, S. (2017). Environmental pH modulation by pathogenic fungi as a strategy to conquer the host. PLoS Pathogens, 13(2), Article e1006149. https://doi.org/10.1371/journal.ppat.1006149 
215. Vylkova, S., & Lorenz, M. C. (2014). Modulation of phagosomal pH by Candida albicans promotes hyphal morphogenesis and requires Stp2p, a regulator of amino acid transport. PLoS Pathogens, 10(3), Article e1003995. https://doi.org/10.1371/journal.ppat.1003995 
216. Vylkova, S., Carman, A. J., Danhof, H. A., et al. (2011). The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. mBio, 2(3), Article e00055-11. https://doi.org/10.1128/mBio.00055-11 
217. Walker, A., & Leakey, R. (1993). The Nariokotome Homo erectus skeleton. Harvard University Press.
218. Weiberg, A., Wang, M., Lin, F. M., et al. (2013). Fungal small RNAs suppress plant immunity by hijacking host RNA interference pathways. Science, 342(6154), 118–123. https://doi.org/10.1126/science.1239705 
219. Weinberger, M. H., & Fineberg, N. S. (1991). Sodium and volume sensitivity of blood pressure: Age and pressure change over time. Hypertension, 18(1), 67–71. https://doi.org/10.1161/01.hyp.18.1.67 
220. Wernecke, B., et al. (2025). Fungal Argonaute proteins act in bidirectional cross-kingdom RNA interference during plant infection. Proceedings of the National Academy of Sciences, 122(17), Article e2422756122. https://doi.org/10.1073/pnas.2422756122 
221. WHO. (2022). WHO fungal priority pathogens list to guide research, development and public health action. World Health Organization. ISBN: 978-92-4-006024-1. https://www.who.int/publications/i/item/9789240060241 
222. Williams, R. J., Dickinson, K., Kinsman, O. S., Bramley, T. A., Menzies, G. S., & Adams, D. J. (1990). Receptor-mediated elevation of adenylate cyclase by luteinizing hormone in Candida albicans. Journal of General Microbiology, 136, 2143–2148.
223. Wilson, K. E., Maslin, M. A., Leng, M. J., et al. (2014). East African lake evidence for Pliocene millennial-scale climate variability. Geology, 42(11), 955–958. https://doi.org/10.1130/G35915.1 
224. Wurster, S., Lyos, S., Albert, N. D., & Kontoyiannis, D. P. (2021). Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. Medical Mycology, 59(1), 102–105. https://doi.org/10.1093/mmy/myaa060 
225. Yoo, H. J., et al. (2019). Short-term antifungal treatments of caprylic acid with carvacrol or thymol induce synergistic 6-log reduction of pathogenic Candida albicans by cell membrane disruption and efflux pump inhibition. Cellular Physiology and Biochemistry, 53(2), 285-300.
226. Yu, Q., et al. (2014). Interaction among the vacuole, the mitochondria, and the oxidative stress response is governed by the transient receptor potential channel in Candida albicans. Free Radical Biology and Medicine, 77, 152–167. https://doi.org/10.1016/j.freeradbiomed.2014.09.011 
227. Zaman, L., Meyer, J. R., Devangam, S., Bryson, D. M., Lenski, R. E., & Ofria, C. (2014). Coevolution drives the emergence of complex traits and promotes evolvability. PLoS Biology, 12(12), e1002023. https://doi.org/10.1371/journal.pbio.1002023 
228. Zarnowski, R., et al. (2018). Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biology, 16(10), Article e2006872. https://doi.org/10.1371/journal.pbio.2006872 
229. Zarnowski, R., et al. (2022). A common vesicle proteome drives fungal biofilm development. Proceedings of the National Academy of Sciences, 119(38), Article e2211424119. https://doi.org/10.1073/pnas.2211424119 
230. Zarnowski, R., Noll, A., Chevrette, M. G., et al. (2021). Coordination of fungal biofilm development by extracellular vesicle cargo. Nature Communications, 12, Article 6235. https://doi.org/10.1038/s41467-021-26525-z 
231. Zelante, T., Iannitti, R. G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., D’Angelo, C., Massi-Benedetti, C., Fallarino, F., Carvalho, A., Puccetti, P., & Romani, L. (2013). Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity, 39(2), 372–385. https://doi.org/10.1016/j.immuni.2013.08.003 
232. Zhang, X., Essmann, M., Burt, E. T., & Larsen, B. (2000). Estrogen effects on Candida albicans: A potential virulence-regulating mechanism. The Journal of Infectious Diseases, 181(4), 1441–1446. https://doi.org/10.1086/315406 
233. Zhang, X., et al. (2022). Antimicrobial effect of extracellular vesicles derived from human oral mucosal epithelial cells on Candida albicans. Frontiers in Immunology, 13, Article 959962. https://doi.org/10.3389/fimmu.2022.959962 
234. Zhu, Q., Tan, P., Li, Y., et al. (2018). DHX29 functions as an RNA co-sensor for MDA5-mediated EMCV-specific antiviral immunity. PLoS Pathogens, 14(2), Article e1006886. https://doi.org/10.1371/journal.ppat.1006886 
235. Zohary, D., & Hopf, M. (1988). Domestication of plants in the Old World. Oxford University Press.
236. Zohary, D., Hopf, M., & Weiss, E. (2012). Domestication of plants in the Old World (4th ed.). Oxford University Press.

[I am a lucky man.  I have enjoyed 31 years of life that I never would have had without Homo candidus. Will, Kelly, Mom, Bethany, Adelyn, Owen, Oscar, and Auggie, you made my life better, too.  I am honored to have lived the life I have, and I am humbled that I am the one to reintroduce and reveal the knowledge contained in this paper. #TheArchitect]